UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF NEW YORK

	•	
	•	
In re:	:	Chapter 11

PURDUE PHARMA L.P., et al., : Case No. 19-23649 (RDD)

Debtors.¹ : (Jointly Administered)

FOURTH MONTHLY FEE STATEMENT OF KPMG LLP FOR COMPENSATION FOR SERVICES RENDERED AND REIMBURSEMENT OF EXPENSES INCURRED AS TAX CONSULTANT FOR THE DEBTORS AND THE OFFICIAL COMMITTEE OF UNSECURED CREDITORS FOR THE PERIOD FROM APRIL 1, 2020 THROUGH APRIL 30, 2020

Name of Applicant: KPMG LLP

Authorized to Provide Professional Services to:

The Debtors and the Official Committee of

Unsecured Creditors

Date of Retention: February 24, 2020, nunc pro tunc to

December 23, 2019

Period for Which Compensation and April 1, 2020 through

Reimbursement is Sought: April 30, 2020

Amount of Compensation Sought as Actual,

Reasonable, and Necessary: \$ 578,790.45²

Less 20% Holdback: \$ (115,758.09)

Amount of Expense Reimbursement Sought as

Actual, Reasonable, and Necessary: \$ 0.00

Total Fees and Expenses Due: \$ 463,032.36

The Debtors in these cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF L.P. (0495), SVC Pharma L.P. (5717) and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

Amount reflects credit of \$57,147.20 related to updated rates for the following KPMG foreign member firms: Brazil, Germany, Italy, Singapore, Switzerland and the UK in KPMG's 1st, 2nd and 3rd monthly fee applications.

Dated: June 5, 2020

/s/ Howard Steinberg

Howard Steinberg Partner, KPMG LLP 1350 Avenue of the Americas New York, New York 10019 (212) 872-6562

EXHIBIT A

Purdue Pharma L.P. Case No. 19-23649

Summary Of Hours and Discounted Fees Incurred By Professional April 1, 2020 through April 30, 2020

		Country of		Но	ourly Billing	Total		
Professional Person	Position & Department	Origin	Billed Hours		Rate	<u>C</u>	ompensation	
Alejandro Merelles Rodriguez	Senior Associate - Tax	Luxembourg	13.8	\$	640	\$	8,832.00	
Arik Eytan	Partner - Tax	Israel	0.7	\$	555	\$	388.50	
Aroen Rambhadjan	Partner - Tax	Netherlands	8.6	\$	884	\$	7,602.40	
Arpit Desai	Senior Manager - Tax	UK	3.6	\$	750	\$	2,662.50	
Ashley Armfield	Senior Associate - M&A Tax	US	167.9	\$	534	\$	89,658.60	
Becky Holtje	Senior Manager - Washington National Tax	US	17.3	\$	744	\$	12,871.20	
Bela Unell	Senior Manager - Washington National Tax	US	2.4	\$	744	\$	1,785.60	
Carlotta Bertu	Senior Associate - Tax	Italy	17.1	\$	214	\$	3,659.40	
Casey Nunez	Senior Manager - M&A Tax	US	69.5	\$	744	\$	51,708.00	
Christian Schmid	Partner - Int'l Tax	Germany	2.8	\$	817	\$	2,287.60	
Claudio Mengotti	Manager - Tax	Switzerland	20.8	\$	610	\$	12,688.00	
Curt Wilson	Senior Manager - Washington National Tax	US	0.5	\$	744	\$	372.00	
Danielle Moloughney	Associate - Tax	Canada	3.2	\$	172	\$	550.40	
Dawn Krishnamurthy	Manager - M&A Tax	US	4.1	\$	695	\$	2,849.50	
Denis Larkin	Principal - Tax	Australia	2.4	\$	566	\$	1,358.40	
Devon Rowles	Associate - M&A Tax	US	74.0	\$	350	\$	25,900.00	
Diego Lipp	Senior Associate - Tax	Switzerland	4.5	\$	430	\$	1,935.00	
Dong-Ju Shin	Senior Manager - Global Tax	South Korea	3.7	\$	476	\$	1,761.20	
Dora Xu	Senior Associate - Tax	China	2.4	\$	315	\$	756.00	
Douglas Holland	Principal - Washington National Tax	US	15.9	\$	985	\$	15,661.50	
Emilien Lebas	Partner - Tax	Luxembourg	4.2	\$	985	\$	4,137.00	
Eugenio Graziani	Partner - Tax	Italy	2.2	\$	476	\$	1,047.20	
Gavin Little	Managing Director - Tax	UK	4.2	\$	985	\$	4,137.00	
Gordon Lawson	Partner - Tax	Singapore	1.0	\$	791	\$	791.00	
Gregory Bell	Partner - Tax	Canada	1.4	\$	743	\$	1,040.20	
Hanah Lewis	Senior Associate - Tax	Australia	7.8	\$	239	\$	1,864.20	
Howard Steinberg	Partner - M&A Tax	US	3.8	\$	856	\$	3,252.80	
Isaac Hirsch	Managing Director - Int'l Tax	US	131.8	\$	819	\$	107,944.20	
Jess Commisso	Associate - M&A Tax	US	123.5	\$	350	\$	43,225.00	
Jonas Lau	Senior Manager - Tax	Canada	5.3	\$	614	\$	3,254.20	
Joyce Tan	Partner - Tax	China	0.8	\$	985	\$	788.00	
Justin Davis	Partner - Tax	Australia	0.5	\$	655	\$	327.50	
Karl Tong	Manager - Tax	China	3.9	\$	594	\$	2,316.60	
Kees Van Meel	Principal - Int'l Tax	US	0.7	\$	757	\$	529.90	
Kyung-Min Kim	Senior Manager - Tax	South Korea	1.7	\$	476	\$	809.20	
Lorenzo Bellavite	Partner - Tax	Italy	4.1	\$	476	\$	1,951.60	
Lukas van der Veen	Manager - Tax	Netherlands	21.2	\$	565	\$	11,978.00	
Madeleine Latham	Associate - Tax	UK	7.5	\$	343	\$	2,572.50	
Marissa Low	Manager - Tax	Singapore	5.5	\$	247	\$	1,358.50	
Mark Hoffenberg	Principal - Washington National Tax	US	7.9	\$	980	\$	7,742.00	
Massimiliano Bozzola	Associate - Tax	Italy	3.9	\$	172	\$	670.80	
Michael Land	Senior Associate - M&A Tax	US	79.1	\$	534	\$	42,239.40	
Monica Plangman	Associate Director - Bankruptcy	US	2.6	\$	264	\$	686.40	
Nicolas Meer	Paraprofessional - Tax	Switzerland	3.1	\$	220	\$	682.00	

19-23649-shl Doc 1233 Filed 06/05/20 Entered 06/05/20 18:54:25 Main Document Pg 4 of 76

EXHIBIT A

Purdue Pharma L.P. Case No. 19-23649

Summary Of Hours and Discounted Fees Incurred By Professional April 1, 2020 through April 30, 2020

Professional Person	on Position & Department		Total Billed Hours	Ho	Hourly Billing Rate		Total ompensation
Paul Harden	Managing Director - Tax	UK	7.1	\$	985	\$	6,944.25
Paul Kunkel	Senior Manager - Washington National Tax	US	1.6	\$	744	\$	1,190.40
Pete DiMatteo	Manager - Int'l Tax	US	130.2	\$	650	\$	84,630.00
Rob Keller	Managing Director - Washinigton National Tax	US	4.2	\$	893	\$	3,750.60
Robin Lijzenga	Manager - Tax	Luxembourg	8.8	\$	730	\$	6,424.00
Roger Lee	Manager - Tax	Singapore	2.7	\$	371	\$	1,001.70
Sam Tyler	Partner - Tax	Canada	1.7	\$	743	\$	1,263.10
Sara Gonzalez Perez	Associate - Tax	Luxembourg	12.5	\$	380	\$	4,750.00
Sayan Basak	Associate - Tax	Singapore	3.9	\$	124	\$	483.60
Serena Xu	Senior Manager - Washington National Tax	US	2.0	\$	744	\$	1,488.00
Simon Juon	Partner - Tax	Switzerland	3.3	\$	850	\$	2,805.00
Sonia Stricker	Associate - Tax	Germany	19.6	\$	233	\$	4,566.80
Teresa Williams	Associate - Bankruptcy	US	1.5	\$	140	\$	210.00
Thomas Heubach	Senior Manager - Tax	Germany	18.0	\$	653	\$	11,754.00
Tracy Stone	Principal - Washington National Tax	US	5.4	\$	906	\$	4,892.40
Wendy Shaffer	Manager - Bankruptcy	US	39.8	\$	202	\$	8,039.60
Yaniv Hertz	Partner - Tax	Israel	1.0	\$	555	\$	555.00
Zafer Ülgen	Associate - Tax	Netherlands	1.8	\$	309	\$	556.20
Subtotal of Hours and Discou	inted Fees		1,127.9			\$	635,937.65
Credit related to updated foreig	n member firm rates in KPMG's 1st, 2nd and 3rd m	onthly fee appli	cations (Exhibit	C1)		\$	(57,147.20)
Total Discounted Fees						\$	578,790.45
Out of Pocket Expenses						\$	-
Total Fees and Out of Pocket			\$	578,790.45			
Less Holdback Adjustment (20			\$	(115,758.09)			
Net Requested Fees & Out of Pocket Expenses						\$	463,032.36
Blended Hourly Rate				\$	513.16		

19-23649-shl Doc 1233 Filed 06/05/20 Entered 06/05/20 18:54:25 Main Document Pg 5 of 76

EXHIBIT B

Purdue Pharma L.P. Case No. 19-23649

Summary of Hours and Discounted Fees Incurred by Category April 1, 2020 through April 30, 2020

		Total	Total Fees		
Category	Exhibit	Billed Hours]	Requested	
Bankruptcy Tax Consulting Services	C1	1,080.3	\$	566,936.65	
Non -Working Travel Time	C2	0.0	\$	-	
Retention Services	C3	0.0	\$	-	
Fee Application Preparation Services	C4	47.6	\$	11,853.80	
Total		1,127.9	\$	578,790.45	

KPMG LLP Monthly Fee Statement Page 3 of 74

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Claudio Mengotti	04/01/20	Email correspondence with D. Rowles and J. Commisso (KPMG US) regarding preparation and scope of call on April 3 with I. Hirsch, C. Nunez, C. Mengotti, S. Juon, A. Armfield and J. Commisso (KPMG) concerning potential Swiss tax consequences	0.3	\$610	\$ 183.00
Jess Commisso	04/01/20	Correspondence with KPMG member firms to confirm receipt of certain information requests pursuant to follow-ups after a phone call with Norton Rose.	0.8	\$350	\$ 280.00
Michael Land	04/01/20	Updated the information request list to reflect information received in the trust presentations as of 4/1/2020.	0.9	\$534	\$ 480.60
Isaac Hirsch	04/01/20	Prepared for call with Norton Rose Fulbright by reviewing global and trust information request lists (0.6) and Norton Rose cash tax cost calculations (0.7)	1.3	\$819	\$ 1,064.70
Mark Hoffenberg	04/01/20	Conference call with L. Kelly (Norton Rose Fulbright), I. Hirsch (KPMG), C. Nunez (KPMG), P. Kunkel (KPMG), H. Steinberg (KPMG) - partial attendance, T. Stone (KPMG) - partial attendance and M. Hoffenberg (KPMG) - partial attendance to review KPMG's global tax information request list for purposes of cash tax modeling, including responses to same, and strategy for obtaining additional information.	0.5	\$980	\$ 490.00
Tracy Stone	04/01/20	Conference call with L. Kelly (Norton Rose Fulbright), I. Hirsch (KPMG), C. Nunez (KPMG), P. Kunkel (KPMG), H. Steinberg (KPMG) - partial attendance, T. Stone (KPMG) - partial attendance and M. Hoffenberg (KPMG) - partial attendance to review KPMG's global tax information request list for purposes of cash tax modeling, including responses to same, and strategy for obtaining additional information.	1.0	\$906	\$ 906.00
Howard Steinberg	04/01/20	Conference call with L. Kelly (Norton Rose Fulbright), I. Hirsch (KPMG), C. Nunez (KPMG), P. Kunkel (KPMG), H. Steinberg (KPMG) - partial attendance, T. Stone (KPMG) - partial attendance and M. Hoffenberg (KPMG) - partial attendance to review KPMG's global tax information request list for purposes of cash tax modeling, including responses to same, and strategy for obtaining additional information.	1.0	\$856	\$ 856.00
Casey Nunez	04/01/20	Conference call with L. Kelly (Norton Rose Fulbright), I. Hirsch (KPMG), C. Nunez (KPMG), P. Kunkel (KPMG), H. Steinberg (KPMG) - partial attendance, T. Stone (KPMG) - partial attendance and M. Hoffenberg (KPMG) - partial attendance to review KPMG's global tax information request list for purposes of cash tax modeling, including responses to same, and strategy for obtaining additional information.	1.6	\$744	\$ 1,190.40

Purdue Pharma L.P. Case No. 19-23649

Bankruptcy Tax Consulting Services April 1, 2020 through April 30, 2020

Name	Date	Description	Hours	Rate	Amount
Isaac Hirsch	04/01/20	Conference call with L. Kelly (Norton Rose Fulbright), I. Hirsch (KPMG), C. Nunez (KPMG), P. Kunkel (KPMG), H. Steinberg (KPMG) - partial attendance, T. Stone (KPMG) - partial attendance and M. Hoffenberg (KPMG) - partial attendance to review KPMG's global tax information request list for purposes of cash tax modeling, including responses to same, and strategy for obtaining additional information.	1.6	\$819	\$ 1,310.40
Paul Kunkel	04/01/20	Conference call with L. Kelly (Norton Rose Fulbright), I. Hirsch (KPMG), C. Nunez (KPMG), P. Kunkel (KPMG), H. Steinberg (KPMG) - partial attendance, T. Stone (KPMG) - partial attendance and M. Hoffenberg (KPMG) - partial attendance to review KPMG's global tax information request list for purposes of cash tax modeling, including responses to same, and strategy for obtaining additional information.	1.6	\$744	\$ 1,190.40
Casey Nunez	04/01/20	Updated global information request list based on results of conversation with Norton Rose.	2.2	\$744	\$ 1,636.80
Ashley Armfield	04/01/20	Updating open items in cash tax model to reflect results of discussions with multiple KPMG country specialists (Canada, Singapore, Netherlands, Germany).	2.2	\$534	\$ 1,174.80
Pete DiMatteo	04/01/20	Perform international tax manager review and concurrently revised the global structuring deck depicting contemplated dispositions, including revisions related to local country tax considerations.	3.2	\$650	\$ 2,080.00
Isaac Hirsch	04/01/20	Perform Managing Director review of updates to global structure deck, as of 4/1/2020, which incorporated US tax comments and advice from various local country tax experts in, e.g., the UK, Switzerland, Canada, and Germany.	3.3	\$819	\$ 2,702.70
Pete DiMatteo	04/01/20	3.8 Perform international tax manager review and concurrently revise to global structuring deck depicting contemplated dispositions, including revisions to U.S. federal income tax (USFIT) considerations.	3.8	\$650	\$ 2,470.00
Ashley Armfield	04/01/20	Revised the Purdue cash tax model to reflect updates in income classification by ultimate shareholder.	3.9	\$534	\$ 2,082.60
Lukas van der Veen	04/02/20	Draft response to e-mail from D. Rowles (KPMG US) regarding current Dutch tax group re what is the most recent Corporate Income Tax (CIT) return available in the sharefile with respect to a potential disposition entity.	0.3	\$565	\$ 169.50
Ashley Armfield	04/02/20	Updating information request list for additional entity classification requests to be provided to Norton Rose.	0.3	\$534	\$ 160.20

KPMG LLP Monthly Fee Statement Page 5 of 74

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Gavin Little	04/02/20	Call with A. Desai (KPMG UK) to discuss progress of the project including matters discussed with the US team (to confirm whether any further potential taxes should be raised in the model) and background for any subsequent managing director reviews of the model provided by the KPMG US team.	0.6	\$985	\$ 591.00
Arpit Desai	04/02/20	Call with G. Little (KPMG UK) to discuss progress of the project including matters discussed with the US team (to confirm whether any further potential taxes should be raised in the model) and background for any subsequent managing director reviews of the model provided by the KPMG US team.	0.6	\$750	\$ 450.00
Lukas van der Veen	04/02/20	Review information included in the Sharefile, as of 4/2/2020, to determine the most recent return available for a potential Dutch disposition entity.	0.6	\$565	\$ 339.00
Jess Commisso	04/02/20	Summarizing discussion points from phone call with the KPMG UK specialists pursuant to highlighting relevant tax detail to be used in the cash tax model in order to provide to KPMG project team.	0.6	\$350	\$ 210.00
Michael Land	04/02/20	Review of updated information request list, as of 4/2/2020, for purposes of determining information received and what is outstanding.	0.7	\$534	\$ 373.80
Arpit Desai	04/02/20	Call with I. Hirsch, A. Armfield and J. Commisso (KPMG US) and A. Desai, M. Latham, (KPMG UK) regarding UK tax consequences of a potential UK disposition pursuant to incorporation of appropriate rates into the cash tax model.	0.9	\$750	\$ 675.00
Madeleine Latham	04/02/20	Call with I. Hirsch, A. Armfield and J. Commisso (KPMG US) and A. Desai, M. Latham, (KPMG UK) regarding UK tax consequences of a potential UK disposition pursuant to incorporation of appropriate rates into the cash tax model.	0.9	\$343	\$ 308.70
Ashley Armfield	04/02/20	Call with I. Hirsch, A. Armfield and J. Commisso (KPMG US) and A. Desai, M. Latham, (KPMG UK) regarding UK tax consequences of a potential UK disposition pursuant to incorporation of appropriate rates into the cash tax model.	0.9	\$534	\$ 480.60
Isaac Hirsch	04/02/20	Call with I. Hirsch, A. Armfield and J. Commisso (KPMG US) and A. Desai, M. Latham, (KPMG UK) regarding UK tax consequences of a potential UK disposition pursuant to incorporation of appropriate rates into the cash tax model.	0.9	\$819	\$ 737.10
Jess Commisso	04/02/20	Call with I. Hirsch, A. Armfield and J. Commisso (KPMG US) and A. Desai, M. Latham, (KPMG UK) regarding UK tax consequences of a potential UK disposition pursuant to incorporation of appropriate rates into the cash tax model.	0.9	\$350	\$ 315.00

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Lukas van der Veen	04/02/20	Respond to e-mail from D. Rowles (KPMG US) regarding information available on Mundipharma DC BV, including a review of the KPMG sharefile.	0.9	\$565	\$ 508.50
Casey Nunez	04/02/20	Updates to global information request list based on feedback from local country experts in response to Norton Rose comments from April 1st call.	1.2	\$744	\$ 892.80
Dawn Krishnamurthy	04/02/20	Manager review of most recent version of global structure deck and concurrently provide comments regarding same.	1.9	\$695	\$ 1,320.50
Isaac Hirsch	04/02/20	Performed Managing Director review of updates to the global structure deck as of 4/2/2020, which incorporates US tax comments and advice from various local country tax experts in, e.g., the UK, Switzerland, Canada, and Germany).	2.2	\$819	\$ 1,801.80
Jess Commisso	04/02/20	Updates to the cash tax model with regards to newly received tax implications information from local country specialists.	2.6	\$350	\$ 910.00
Isaac Hirsch	04/02/20	Perform Managing Director review of updates to cash tax model for advice provided by local country experts in Germany	2.8	\$819	\$ 2,293.20
Pete DiMatteo	04/02/20	Perform international tax manager review and concurrently revised the latest version of global structuring deck depicting contemplated dispositions, including revisions related to German / UK tax considerations	3.4	\$650	\$ 2,210.00
Ashley Armfield	04/02/20	Updating cash tax model for Germany asset sale disposition based on updated draft provided by Director as of 4/2/2020.	3.8	\$534	\$ 2,029.20
Pete DiMatteo	04/02/20	Continue (from 4/1/20) to perform international tax manager review and revisions to latest version of global structuring deck depicting contemplated dispositions	3.9	\$650	\$ 2,535.00
Jess Commisso	04/02/20	Updates to the cash tax model pursuant to newly received tax implications information from local country specialists as of 4/2/2020.	3.9	\$350	\$ 1,365.00
Claudio Mengotti	04/03/20	Follow-up discussion with S. Juon (KPMG Switzerland) regarding Swiss potential tax optimization measures in connection with measures discussed during call with KPMG US (on same day) concerning potential Swiss tax consequences for a disposition of Switzerland entities.	0.3	\$610	\$ 183.00
Simon Juon	04/03/20	Follow-up discussion with C. Mengotti (KPMG Switzerland) regarding Swiss potential tax optimization measures in connection with measures discussed during call with KPMG US (on same day) concerning potential Swiss tax consequences for a disposition of Switzerland entities.	0.3	\$850	\$ 255.00

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Claudio Mengotti	04/03/20	Preparation for call with I. Hirsch, C. Nunez, C. Mengotti, S. Juon, A. Armfield and J. Commisso (all internal KPMG) concerning Swiss tax consequences by preparing main proposed structuring options / talking points (as per KPMG US' report) while concurrently noting some questions (relevant from a Swiss tax perspective)	0.3	\$610	\$ 183.00
Jess Commisso	04/03/20	Summarized details/findings resulting from phone call with the Swiss specialists pursuant to highlighting relevant tax detail to be used in the cash tax model in preparation to provide to KPMG project team.	0.7	\$350	\$ 245.00
Claudio Mengotti	04/03/20	Call with I. Hirsch, C. Nunez, A. Armfield and J. Commisso (KPMG US) and C. Mengotti, S. Juon (KPMG Switzerland) regarding potential Swiss tax consequences for a disposition of Switzerland entities pursuant to incorporation of appropriate rates into the cash tax model.	0.8	\$610	\$ 488.00
Simon Juon	04/03/20	Call with I. Hirsch, C. Nunez, A. Armfield and J. Commisso (KPMG US) and C. Mengotti, S. Juon (KPMG Switzerland) regarding potential Swiss tax consequences for a disposition of Switzerland entities pursuant to incorporation of appropriate rates into the cash tax model.	0.8	\$850	\$ 680.00
Casey Nunez	04/03/20	Call with I. Hirsch, C. Nunez, A. Armfield and J. Commisso (KPMG US) and C. Mengotti, S. Juon (KPMG Switzerland) regarding potential Swiss tax consequences for a disposition of Switzerland entities pursuant to incorporation of appropriate rates into the cash tax model.	0.8	\$744	\$ 595.20
Isaac Hirsch	04/03/20	Call with I. Hirsch, C. Nunez, A. Armfield and J. Commisso (KPMG US) and C. Mengotti, S. Juon (KPMG Switzerland) regarding potential Swiss tax consequences for a disposition of Switzerland entities pursuant to incorporation of appropriate rates into the cash tax model.	0.8	\$819	\$ 655.20
Jess Commisso	04/03/20	Call with I. Hirsch, C. Nunez, A. Armfield and J. Commisso (KPMG US) and C. Mengotti, S. Juon (KPMG Switzerland) regarding potential Swiss tax consequences for a disposition of Switzerland entities pursuant to incorporation of appropriate rates into the cash tax model.	0.8	\$350	\$ 280.00
Isaac Hirsch	04/03/20	Conference call with I. Hirsch and P. DiMatteo (both KPMG) to discuss PowerPoint presentation depicting contemplated dispositions of various entities in multiple jurisdictions, including anticipated U.S. and foreign tax considerations and revisions to same.	2.4	\$819	\$ 1,965.60

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Pete DiMatteo	04/03/20	Conference call with I. Hirsch and P. DiMatteo (both KPMG) to discuss PowerPoint presentation depicting contemplated dispositions of various entities in multiple jurisdictions, including anticipated U.S. and foreign tax considerations and revisions to same.	2.4	\$650	\$ 1,560.00
Isaac Hirsch	04/03/20	Performed Managing Director review of anticipated U.S. and foreign tax considerations in global structure deck, including advice from local country tax experts in the UK, Switzerland, Germany, and Luxembourg.	2.9	\$819	\$ 2,375.10
Ashley Armfield	04/03/20	Updating cash tax model to reflect equity disposition of a German mundipharma entity.	3.1	\$534	\$ 1,655.40
Paul Harden	04/06/20	Meeting with A. Desai, P. Harden and M. Latham (all KPMG UK) to discuss trust documents provided by the KPMG US team and scope of the review to be undertaken on these documents based on discussions with the KPMG US team.	0.3	\$985	\$ 246.25
Arpit Desai	04/06/20	Meeting with A. Desai, P. Harden and M. Latham (all KPMG UK) to discuss trust documents provided by the KPMG US team and scope of the review to be undertaken on these documents based on discussions with the KPMG US team.	0.3	\$750	\$ 187.50
Madeleine Latham	04/06/20	Meeting with A. Desai, P. Harden and M. Latham (all KPMG UK) to discuss trust documents provided by the KPMG US team and scope of the review to be undertaken on these documents based on discussions with the KPMG US team.	0.3	\$343	\$ 85.75
Danielle Moloughney	04/06/20	Review of Canadian entities' financial statements for the parties to which intercompany receivables and payables are due to and from in order to aid J. Lau (KPMG Canada).	0.8	\$172	\$ 137.60
Casey Nunez	04/06/20	Performed senior manager review of local country specialist comments on information request list	1.1	\$744	\$ 818.40
Pete DiMatteo	04/06/20	Perform international tax manager review and concurrently revised the global structuring deck depicting contemplated dispositions.	2.2	\$650	\$ 1,430.00
Casey Nunez	04/06/20	Performed M&A senior manager review of most recent updates to the Purdue global structure deck and concurrently draft review comments.	2.3	\$744	\$ 1,711.20
Isaac Hirsch	04/06/20	Performed Managing Director review of updates to global structure deck for advice provided by local country tax experts in the UK, Germany, and Luxembourg as of 4/6/2020.	2.3	\$819	\$ 1,883.70
Sonia Stricker	04/06/20	Drafted answers to questions by P. DiMatteo (KPMG US) on German tax consequences regarding the proposed disposal of a specific German entity.	2.8	\$233	\$ 652.40
Isaac Hirsch	04/06/20	Performed Managing Director review of updates to cash tax model for advice provided by local country tax experts in Canada and Germany as of 4/6/2020.	3.1	\$819	\$ 2,538.90

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Pete DiMatteo	04/06/20	Performed international tax manager review and concurrently revised the global structuring deck depicting contemplated dispositions with focus on USFIT and local country tax consequences and considerations	3.2	\$650	\$ 2,080.00
Simon Juon	04/07/20	Performed Partner review of draft e-mail comments to respond to follow-up questions from D. Rowles (KPMG US) with details regarding implementing of specifics concerning potential Swiss tax consequences into structuring report update.	0.3	\$850	\$ 255.00
Ashley Armfield	04/07/20	Drafted email to German tax specialists relating to cash tax model calculation of German disposition.	0.4	\$534	\$ 213.60
Claudio Mengotti	04/07/20	Incorporation of review comments (from S. Juon - KPMG Switzerland) into structuring report update in connection with follow-up questions of D. Rowles (KPMG US) regarding Swiss tax consequences for a potential disposition of Switzerland Mundipharma entities pursuant to incorporation of appropriate rates into the cash tax model.	0.4	\$610	\$ 244.00
Dawn Krishnamurthy	04/07/20	Review of information provided by Norton Rose in order to gain insight related to the financial positions of various Mundipharma entities and concurrently draft and email to A. Armfield and M. Land (both KPMG) with follow-up question.	0.4	\$695	\$ 278.00
Casey Nunez	04/07/20	Performed senior manager review of trust name matching information provided by Akin Gump	0.7	\$744	\$ 520.80
Jess Commisso	04/07/20	Revised the information request list to incorporate tax information received versus not yet received for high-priority jurisdictions as of 4/7/2020.	0.8	\$350	\$ 280.00
Casey Nunez	04/07/20	Performed M&A senior manager review of updates to global structure deck related to the German structure with foreign tax consequences	0.9	\$744	\$ 669.60
Casey Nunez	04/07/20	Perform M&A senior manager review of updates to global structure deck related to the Canadian structure with foreign tax consequences	1.1	\$744	\$ 818.40
Michael Land	04/07/20	Review of designated portion of information uploaded to the virtual data room as of 4/7/2020 to identify / assess relevant tax information received.	1.1	\$534	\$ 587.40
Michael Land	04/07/20	Updates to information request list to reflect the receipt of information uploaded to the data room on April 7, 2020.	1.3	\$534	\$ 694.20

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Claudio Mengotti	04/07/20	Drafting comments to respond to follow-up questions from D. Rowles (KPMG US) regarding Swiss tax consequences related to potential restructuring options of Switzerland Mundipharma entities pursuant to incorporation of appropriate rates into the cash tax model (0.9) incorporation of aforementioned comments and further clarifications concerning potential Swiss tax consequences into the structuring report update as per April 8, 2020 (0.8).	1.7	\$610	\$ 1,037.00
Isaac Hirsch	04/07/20	Performed Managing Director review of updates to German cash tax cost calculation in preparation for circulating same to local country tax experts.	2.1	\$819	\$ 1,719.90
Jess Commisso	04/07/20	Updates to the Purdue cash tax model for foreign tax consequences of disposition entities based on discussion with local tax experts.	2.1	\$350	\$ 735.00
Sonia Stricker	04/07/20	Prepare comments related to the cash tax model of the potential disposal of a German entity (provided by A. Armfield - KPMG US) - related to proposed Deal 1	2.3	\$233	\$ 535.90
Sonia Stricker	04/07/20	Prepared comments related to the cash tax model of the potential disposal of a German entity (provided by A. Armfield - KPMG US) - related to proposed Deal 2	2.8	\$233	\$ 652.40
Ashley Armfield	04/07/20	Updating cash tax model for manager comments for a potential disposition of German entity (2.1) and inputs for certain tax attributes (0.8).	2.9	\$534	\$ 1,548.60
Devon Rowles	04/07/20	Updating the virtual data room tracker to include new provided by client documentation received as of 4/7/2020 that includes exact file name / location in the data room to facilitate project team review	2.9	\$350	\$ 1,015.00
Paul Harden	04/07/20	Managing Director review (from a UK tax perspective) of trust documentation provided by the KPMG US team and concurrently writing up analysis of potential tax implications of distributions	3.0	\$985	\$ 2,955.00
Pete DiMatteo	04/07/20	Perform international tax manager review and concurrently revised the global structuring deck depicting contemplated dispositions, including various revisions to deck and depictions therein.	3.2	\$650	\$ 2,080.00
Pete DiMatteo	04/07/20	Performed international tax manager review and concurrently revised the global structuring deck depicting contemplated dispositions, including various correspondence with local teams (on an as-needed basis).	3.4	\$650	\$ 2,210.00
Lukas van der Veen	04/08/20	Review incoming e-mail from KPMG US on potential impact of Netherlands Covid-19 measures for Dutch entities.	0.2	\$565	\$ 113.00

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Devon Rowles	04/08/20	Correspondence via email with local country specialists regarding new tax legislation in response to COVID-19 that may impact the disposition analysis and related tax consequences	0.6	\$350	\$ 210.00
Michael Land	04/08/20	Review of documentation uploaded to the data room as of 4/8/2020 to identify / assess relevant tax information received.	1.1	\$534	\$ 587.40
Michael Land	04/08/20	Performed senior associate review of the master tax summary model with focus on tax profile of target entities	1.2	\$534	\$ 640.80
Isaac Hirsch	04/08/20	Conference call with I. Hirsch and P. DiMatteo (both KPMG) to discuss the PowerPoint presentation depicting contemplated dispositions of various UK entities, including anticipated foreign tax considerations and revisions required to same.	1.4	\$819	\$ 1,146.60
Pete DiMatteo	04/08/20	Conference call with I. Hirsch and P. DiMatteo (both KPMG) to discuss the PowerPoint presentation depicting contemplated dispositions of various UK entities, including anticipated foreign tax considerations and revisions required to same.	1.4	\$650	\$ 910.00
Thomas Heubach	04/08/20	Perform Senior Manager review of answers prepared by S. Stricker (KPMG Germany) to questions by P. DiMatteo (KPMG US) on German tax consequences regarding the proposed disposal of a Dutch entity (1.4) and draft email to P. DiMatteo (KPMG US) related to same (0.2).	1.6	\$653	\$ 1,044.80
Pete DiMatteo	04/08/20	Performed international tax manager review of various UK tax considerations associated with contemplated dispositions (1.2); correspondence via email with UK tax advisers regarding same (0.4).	1.6	\$650	\$ 1,040.00
Devon Rowles	04/08/20	1.8 Updating the information request list to include additional tax documents received in the virtual data room as of $4/8/2020$	1.8	\$350	\$ 630.00
Isaac Hirsch	04/08/20	Performed Managing Director review of changes to global structure deck reflecting updated advice from local country tax experts including the Netherlands and the UK	1.9	\$819	\$ 1,556.10
Sonia Stricker	04/08/20	Prepare comments regarding German measures to respond to COVID-19 including relevance for the potential disposal of a German entity requested by D. Rowles (KPMG US).	2.3	\$233	\$ 535.90
Isaac Hirsch	04/08/20	Updated the cash tax cost calculation for computations related to sale of Dutch entity to include advice from KPMG member firm.	2.7	\$819	\$ 2,211.30
Devon Rowles	04/08/20	2.9 Created list of provided by client documents received in the virtual data room on 4/8/2020 to facilitate project team review	2.9	\$350	\$ 1,015.00
Jess Commisso	04/08/20	Incorporation of certain tax attributes (provided by the client) into our existing tax attribute file to facilitate analysis of such attributes.	2.9	\$350	\$ 1,015.00

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Pete DiMatteo	04/08/20	Performed international tax manager review and concurrently revised the PowerPoint presentation depicting various contemplated transactions with respect to multiple UK subsidiaries	3.1	\$650	\$ 2,015.00
Jess Commisso	04/08/20	Incorporation of certain (additional) tax attributes (provided by the client) into our existing tax attribute file to facilitate analysis of such attributes	3.9	\$350	\$ 1,365.00
Alejandro Merelles Rodriguez	04/09/20	Senior Associate level review of the comments inserted in the Mundipharma Disposition Analysis Master slide deck sent by the U.S. team as agreed in the meeting with the rest of the Luxembourg team	0.2	\$640	\$ 128.00
Robin Lijzenga	04/09/20	Drafted email on COVID-19 measures, as requested by the KPMG U.S. team	0.3	\$730	\$ 219.00
Lukas van der Veen	04/09/20	Performed Manager review of e-mail prepared by Z. Ülgen (KPMG Netherlands) which summarizes Netherlands Covid-19 measures	0.4	\$565	\$ 226.00
Sara Gonzalez Perez	04/09/20	Reviewed and concurrently drafted comments on the Mundipharma Disposition Analysis Master slide deck sent by the U.S. team (as agreed in the meeting with the rest of the Luxembourg team).	0.4	\$380	\$ 152.00
Alejandro Merelles Rodriguez	04/09/20	Senior Associate level review of draft email to the U.S team detailing Luxembourg main conclusions / proposed changes to the Mundipharma Disposition Analysis Master slide deck	0.4	\$640	\$ 256.00
Casey Nunez	04/09/20	Senior Manager review of draft of Australia capitalization document request response to specify additional information needs.	0.4	\$744	\$ 297.60
Alejandro Merelles Rodriguez	04/09/20		0.5	\$640	\$ 320.00
Emilien Lebas	04/09/20	Meeting with E. Lebas, R. Lijzenga, A. Merelles and S. Perez (all KPMG Luxembourg) to decide on the final approach to be taken as regards the Mundipharma Disposition Analysis Master slide deck to send back to the U.S. team	0.5	\$985	\$ 492.50
Robin Lijzenga	04/09/20	Meeting with E. Lebas, R. Lijzenga, A. Merelles and S. Perez (all KPMG Luxembourg) to decide on the final approach to be taken as regards the Mundipharma Disposition Analysis Master slide deck to send back to the U.S. team	0.5	\$730	\$ 365.00
Sara Gonzalez Perez	04/09/20	Meeting with E. Lebas, R. Lijzenga, A. Merelles and S. Perez (all KPMG Luxembourg) to decide on the final approach to be taken as regards the Mundipharma Disposition Analysis Master slide deck to send back to the U.S. team	0.5	\$380	\$ 190.00

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Emilien Lebas	04/09/20	Partner review of the Mundipharma Disposition Analysis Master slide deck sent by the U.S. team based on the comments provided by R. Lijzenga (KPMG Luxembourg)	0.5	\$985	\$ 492.50
Robin Lijzenga	04/09/20	Performed Manager review of the final version of Luxembourg direct tax comments included in the Mundipharma Disposition Analysis Master slide deck sent by the U.S. team	0.5	\$730	\$ 365.00
Robin Lijzenga	04/09/20	Preparation of comments regarding the Mundipharma Disposition Analysis slide deck (sent by KPMG U.S. team) in order to provide back to KPMG US.	0.5	\$730	\$ 365.00
Sara Gonzalez Perez	04/09/20	Draft email to the U.S team detailing our main conclusions / proposed changes to the Mundipharma Disposition Analysis Master slide deck	0.6	\$380	\$ 228.00
Michael Land	04/09/20	Review of Australia financial statements in order to gain insight into capitalization structure for purposes of updating the information request list.	0.6	\$534	\$ 320.40
Casey Nunez	04/09/20	Performed Senior manager review of updated global IRL prior to providing to Norton Rose	0.8	\$744	\$ 595.20
Danielle Moloughney	04/09/20	Review of US slide documentation to ensure commentary is consistent with Canadian thoughts.	0.8	\$172	\$ 137.60
Alejandro Merelles Rodriguez	04/09/20	Meeting with A. Merelles. R. Lijzenga and S. Gonzalez (all KPMG Luxembourg) to review and clarify certain approaches taken on the Mundipharma Disposition Analysis Master slide deck by the U.S. team	1.0	\$640	\$ 640.00
Robin Lijzenga	04/09/20	Meeting with A. Merelles. R. Lijzenga and S. Gonzalez (all KPMG Luxembourg) to review and clarify certain approaches taken on the Mundipharma Disposition Analysis Master slide deck by the U.S. team	1.0	\$730	\$ 730.00
Sara Gonzalez Perez	04/09/20	Meeting with A. Merelles. R. Lijzenga and S. Gonzalez (all KPMG Luxembourg) to review and clarify certain approaches taken on the Mundipharma Disposition Analysis Master slide deck by the U.S. team	1.0	\$380	\$ 380.00
Douglas Holland	04/09/20	Performed WNT International Partner review of U.S. tax consequences of proposed disposition of Canadian business	1.0	\$985	\$ 985.00
Gavin Little	04/09/20	Performing managing director review of the input drafted by M. Latham (KPMG UK) prior to its delivery to the KPMG US team.	1.0	\$985	\$ 985.00
Casey Nunez	04/09/20	Conference call with D. Holland, I. Hirsch, C. Nunez, and P. DiMatteo (KPMG) to review and concurrently discuss Washington National Tax review of PowerPoint presentation depicting contemplated dispositions of various entities.	1.1	\$744	\$ 818.40

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Douglas Holland	04/09/20	Conference call with D. Holland, I. Hirsch, C. Nunez, and P. DiMatteo (KPMG) to review and concurrently discuss Washington National Tax review of PowerPoint presentation depicting contemplated dispositions of various entities.	1.1	\$985	\$ 1,083.50
Isaac Hirsch	04/09/20	Conference call with D. Holland, I. Hirsch, C. Nunez, and P. DiMatteo (KPMG) to review and concurrently discuss Washington National Tax review of PowerPoint presentation depicting contemplated dispositions of various entities.	1.1	\$819	\$ 900.90
Pete DiMatteo	04/09/20	Conference call with D. Holland, I. Hirsch, C. Nunez, and P. DiMatteo (KPMG) to review and concurrently discuss Washington National Tax review of PowerPoint presentation depicting contemplated dispositions of various entities.	1.1	\$650	\$ 715.00
Jess Commisso	04/09/20	Continue, from same day, to update the cash tax model for foreign tax consequences of disposition entities based on discussion with local tax experts.	1.1	\$350	\$ 385.00
Michael Land	04/09/20	Performed senior associate review of updated tax summary model with focus on tax posture of the company	1.1	\$534	\$ 587.40
Zafer Ülgen	04/09/20	Draft e-mail for KPMG US which summarizes the potential impact of the Dutch Covid-19 measures for Dutch companies.	1.2	\$309	\$ 370.80
Claudio Mengotti	04/09/20	Perform high level tax analysis and concurrently draft review comments (in an email) on Swiss extraordinary tax relief measures in connection with the Corona-Virus outbreak	1.2	\$610	\$ 732.00
Christian Schmid	04/09/20	Perform Partner review of comments regarding Cash tax model of the proposed disposal of German entities provided by A. Armfield (KPMG US).	1.2	\$817	\$ 980.40
Casey Nunez	04/09/20	Reviewed provided UK tax return documentation for purposes of updating information request list.	1.2	\$744	\$ 892.80
Alejandro Merelles Rodriguez	04/09/20	Senior Associate level review of the final Luxembourg direct tax comments included in the Mundipharma Disposition Analysis Master slide deck sent by the U.S. team	1.2	\$640	\$ 768.00
Casey Nunez	04/09/20	Performed M&A senior manager review of updates to global structure deck related to the Singapore structure with foreign tax consequences.	1.3	\$744	\$ 967.20
Thomas Heubach	04/09/20	Perform Senior Manager review of comments prepared by S. Stricker (KPMG Germany) regarding German measures to respond to COVID-19 (1.1) and draft email to D. Rowles regarding the same (0.3).	1.4	\$653	\$ 914.20
Casey Nunez	04/09/20	Performed M&A senior manager review of most recent round of updates to global structure deck related to the Netherlands structure with foreign tax consequences.	1.4	\$744	\$ 1,041.60

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Isaac Hirsch	04/09/20	Performed Managing Director review of updates to cash tax model with regards to German, Canadian, Swiss, Dutch, and US tax comments.	1.8	\$819	\$ 1,474.20
Sonia Stricker	04/09/20	Review of new documentation in data room, as of 4/9/2020, in order to identify any key findings from a German tax perspective - as requested by D. Rowles (KPMG US)	1.8	\$233	\$ 419.40
Jess Commisso	04/09/20	Continued (from previous day) incorporation of certain tax attributes (provided by the client) into our existing tax attribute file to facilitate analysis of such attributes	1.9	\$350	\$ 665.00
Madeleine Latham	04/09/20	(1.9) Drafting additional UK tax analysis to include in the structuring report prepared by KPMG US in response to their feedback on our initial draft and (0.1) provide to G. Little (KPMG UK) via email for review.	2.0	\$343	\$ 686.00
Sara Gonzalez Perez	04/09/20	Performed Associate level review of the final Luxembourg direct tax comments included in the Mundipharma Disposition Analysis Master slide deck sent by the U.S. team	2.0	\$380	\$ 760.00
Pete DiMatteo	04/09/20	Perform international tax manager review and concurrently revised the global structuring deck depicting contemplated dispositions, with respect to updates for comments received from local tax advisors as of 4/9/2020.	2.2	\$650	\$ 1,430.00
Thomas Heubach	04/09/20	Perform Senior Manager review of comments prepared by S. Stricker (KPMG Germany) regarding Cash tax model of the proposed disposal of a German entity provided by A. Armfield (KPMG US).	2.7	\$653	\$ 1,763.10
Isaac Hirsch	04/09/20	Updated the Purdue cash tax model for analysis - with respect to Luxembourg tax advice received as of 4/9/2020.	2.8	\$819	\$ 2,293.20
Jess Commisso	04/09/20	Updates to the Purdue cash tax model for foreign tax consequences of disposition entities based on discussion with local tax experts.	3.9	\$350	\$ 1,365.00
Devon Rowles	04/10/20	Reviewed the virtual data room for tax relevant information received as of 4/10/2020 in order to notify the global KPMG team about tax relevant documents received	0.3	\$350	\$ 105.00
Kees van Meel	04/10/20	Performed Principal review Dutch comments on the slide deck on proposed disposition of a Dutch entity (0.5). Principal review of email draft email to Lukas van der Veen (KPMG Netherlands) regarding the same issue (0.2).	0.7	\$757	\$ 529.90
Pete DiMatteo	04/10/20	Perform international tax manager review and concurrently updated the PowerPoint presentation depicting various contemplated transactions, including local tax adviser comments	1.1	\$650	\$ 715.00
Jess Commisso	04/10/20	Continued (from 4/9) incorporation of certain tax attributes (provided by the client) into our existing tax attribute file to facilitate analysis of such attributes	1.4	\$350	\$ 490.00

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Aroen Rambhadjan	04/10/20	Performed Partner review and concurrently include additional comments on deck (circulated by P. DiMatteo - KPMG US) on potential tax consequences of disposal of a Dutch entity	1.5	\$884	\$ 1,326.00
Lukas van der Veen	04/10/20	Review and concurrently provide comments on Purdue draft deck circulated by P. DiMatteo (KPMG US) on potential tax consequences of disposal of a Dutch entity	1.5	\$565	\$ 847.50
Jess Commisso	04/10/20	Determining classification of ownership through analysis of organization charts for disposition entities to properly allocate income and taxes within the Purdue cash tax model.	1.6	\$350	\$ 560.00
Isaac Hirsch	04/10/20	Updated the Purdue cash tax model with regards to Singapore and UK tax advice received as of 4/10/2020.	2.1	\$819	\$ 1,719.90
Casey Nunez	04/10/20	1.3 Perform M&A senior manager review of most recent round of updates to global structure deck related to the Singapore structure with foreign tax consequences;1.6 Perform M&A senior manager review of most recent round of updates to global structure deck related to the Switzerland structure with foreign tax consequences.	2.9	\$744	\$ 2,157.60
Ashley Armfield	04/10/20	Senior Associate reviewing of cash tax model provided by J. Commisso (KPMG) for potential disposition of Dutch entity.	2.9	\$534	\$ 1,548.60
Isaac Hirsch	04/10/20	Performed Managing Director review of various updated portions of the cash tax model (US and non-US tax analysis).	3.2	\$819	\$ 2,620.80
Casey Nunez	04/10/20	Performed M&A senior manager review of most recent round of updates to global structure deck related to the three United Kingdom disposition structures with foreign tax consequences.	3.4	\$744	\$ 2,529.60
Jonas Lau	04/12/20	Considered Canadian tax comments to slide deck prepared by KPMG US with regards to certain financial aspects.	0.6	\$614	\$ 368.40
Jonas Lau	04/12/20	Reviewed (from Canadian tax perspective) the draft cash tax model prepared by KPMG US and concurrently provided comments / assumptions to be added to same.	2.6	\$614	\$ 1,596.40
Marissa Low	04/13/20	Perform assistant manager review of the draft comments in relation to the Singapore COVID-19 measures prepared by S. Basak (KPMG)	0.4	\$247	\$ 98.80
Dong-Ju Shin	04/13/20	(0.5) Discussion with K. Kim (KPMG South Korea) regarding findings related to additional information uploaded to VDR	0.5	\$476	\$ 238.00
Dong-Ju Shin	04/13/20	Per request from KPMG US (D. Rowles), reviewed additional information uploaded to VDR to identify key data / findings from a South Korean tax perspective.	0.5	\$476	\$ 238.00
Ashley Armfield	04/13/20	Call with A. Armfield and J. Commisso both KPMG) to discuss outstanding items to be updated on cash tax model with respect to two jurisdictions (Netherlands and Switzerland).	0.8	\$534	\$ 427.20

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Jess Commisso	04/13/20	Call with A. Armfield and J. Commisso both KPMG) to discuss outstanding items to be updated on cash tax model with respect to two jurisdictions (Netherlands and Switzerland).	0.8	\$350	\$ 280.00
Sayan Basak	04/13/20	Research on the latest tax measures/policies brought in by the Singapore government to response to the COVID-19 situation to alleviate the problems of the companies and concurrently comment on its impact on the five Singapore entities from a Singapore tax perspective.	0.8	\$124	\$ 99.20
Kyung-Min Kim	04/13/20	(0.5) Discussion with D. Shin (KPMG South Korea) regarding findings related to additional information uploaded to VDR (0.5) Sent an email summarizing the findings to KPMG US (D. Rowles)	1.0	\$476	\$ 476.00
Ashley Armfield	04/13/20	1.3 Senior associate review of Netherlands cash tax model (prepared by J. Commisso - KPMG) prior to sending for Managing director review.	1.3	\$534	\$ 694.20
Sayan Basak	04/13/20	Perform associate review of certain documentation provided in relation to the Singapore Mundipharma entities and concurrently update our comments in relation to the same, where necessary.	2.2	\$124	\$ 272.80
Ashley Armfield	04/13/20	Updating Netherlands cash tax model with regards to Managing director comments received as of 4/13/2020 in preparation to send over to Netherlands tax specialist.	2.2	\$534	\$ 1,174.80
Isaac Hirsch	04/13/20	Performed Managing Director review of updates to Netherlands cash tax cost calculation in preparation for sending to local country tax experts.	2.6	\$819	\$ 2,129.40
Ashley Armfield	04/13/20	Senior Associate review of disposition of Swiss entity in cash tax model in preparation to provide to Managing Director for review.	2.7	\$534	\$ 1,441.80
Isaac Hirsch	04/13/20	Performed Managing Director review of global structure deck for purposes of sending same to advisers (UCC and Purdue legal and financial advisors)	2.9	\$819	\$ 2,375.10
Pete DiMatteo	04/13/20	Performed international tax manager review and concurrently revised the PowerPoint presentation for contemplated Singapore and UK transactions.	3.1	\$650	\$ 2,015.00
Pete DiMatteo	04/13/20	Performed international tax manager review and concurrently revised the PowerPoint presentation for contemplated Canada and Germany transactions	3.2	\$650	\$ 2,080.00
Jess Commisso	04/13/20	Update Purdue cash tax model for foreign tax consequences of the Switzerland disposition entity based on discussion with local tax experts.	3.7	\$350	\$ 1,295.00
Jess Commisso	04/13/20	Updated the Purdue cash tax model for foreign tax consequences of the Netherlands disposition entity based on discussion with local tax experts.	3.7	\$350	\$ 1,295.00

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Sam Tyler	04/14/20	Correspondence via email with J. Lau (KPMG Canada) regarding comments to be provided to KPMG US on next steps relating to cash tax modeling and structure deck.	0.1	\$743	\$ 74.30
Aroen Rambhadjan	04/14/20	Partner review of e-mail prepared by L. van der Veen (KPMG Netherlands) including findings of review of cash tax model on proposed disposal of a Dutch entity	0.3	\$884	\$ 265.20
Sam Tyler	04/14/20	Performed Partner review of new step added by KPMG US to KPMG US slide deck and concurrently providing review comments to J. Lau and D. Moloughney (both KPMG Canada)	0.4	\$743	\$ 297.20
Danielle Moloughney	04/14/20	Updated US slide deck with respect to review comments received from S. Tyler (KPMG Canada)	0.5	\$172	\$ 86.00
Jonas Lau	04/14/20	Review of updated Canadian tax comments, related to slide deck prepared by KPMG US, related to the settlement of certain intercompany items.	0.6	\$614	\$ 368.40
Roger Lee	04/14/20	Perform manager review of the draft comments in relation to the Singapore COVID-19 measures along with draft updated comments prepared by S. Basak (KPMG) and M. Low (KPMG), focusing on the implications of the measures and updated information on the cash tax model/structure deck.	0.7	\$371	\$ 259.70
Ashley Armfield	04/14/20	Updating the Purdue cash tax model for comments received from KPMG foreign member firms as of 4/14/2020 relating to foreign income taxes.	1.0	\$534	\$ 534.00
Jess Commisso	04/14/20	(0.8) Reviewed newly received provided by client documentation in the virtual data room as of 4/14/2020 and (0.4) shared, via email, relevant information with KPMG Project team	1.2	\$350	\$ 420.00
Jess Commisso	04/14/20	Aggregated relevant COVID-19 tax information from local tax experts to identify implications (if any) regarding the disposition of Mundipharma entities.	1.4	\$350	\$ 490.00
Lukas van der Veen	04/14/20	(1.0) Review of cash tax model provided by A. Armfield (KPMG US) on potential Dutch tax consequences of disposal of a Dutch entity; (0.9) draft e-mail sent to A. Armfield (KPMG US) with findings of the review of cash tax model on Dutch tax consequences of potential disposal of a Dutch entity	1.9	\$565	\$ 1,073.50
Ashley Armfield	04/14/20	Updated the Purdue cash tax model with regards to certain potential tax items	1.9	\$534	\$ 1,014.60
Michael Land	04/14/20	Perform senior associate review of updated profit & loss file with focus on potential change to our tax analysis with respect to certain dispositions	2.1	\$534	\$ 1,121.40
Pete DiMatteo	04/14/20	Performed analysis regarding certain potential tax deductions, concurrently performing research - as necessary.	2.2	\$650	\$ 1,430.00

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Pete DiMatteo	04/14/20	Perform international tax manager review and concurrently revised the PowerPoint presentation for contemplated UK transactions, including updated for comments by local tax advisors.	2.3	\$650	\$ 1,495.00
Thomas Heubach	04/14/20	Perform Senior Manager review of German comments regarding the potential disposal of a German entity (provided by P. DiMatteo - KPMG US).	2.3	\$653	\$ 1,501.90
Ashley Armfield	04/14/20	Preparation of cash tax model with respect to Luxembourg tax considerations received as of 4/14/2020.	2.3	\$534	\$ 1,228.20
Jess Commisso	04/14/20	Updates to the cash tax model for foreign tax consequences of Luxembourg ownership based on discussion with local tax experts as of 4/14/2020.	2.6	\$350	\$ 910.00
Isaac Hirsch	04/14/20	Performed Managing Director review of updates to cash tax cost calculation for advice provided by local tax experts in Singapore and Switzerland as of 4/14/2020.	2.8	\$819	\$ 2,293.20
Isaac Hirsch	04/14/20	Performed Managing Director review of updates to global structure deck for incorporation of WNT comments / comments from local country tax experts in Luxembourg	3.1	\$819	\$ 2,538.90
Ashley Armfield	04/14/20	Preparation of disposition of Singapore entity in the Purdue cash tax model.	3.1	\$534	\$ 1,655.40
Sonia Stricker	04/14/20	Review of German comments regarding the proposed disposal of a German entity incorporated into the slide deck (as provided by P. DiMatteo - KPMG US).	3.3	\$233	\$ 768.90
Marissa Low	04/14/20	Perform assistant manager review of certain client documentation provided in relation to the Singapore Mundipharma entities along with the draft updated comments - prepared by S. Basak (KPMG).	3.6	\$247	\$ 889.20
Devon Rowles	04/15/20	Communication via email with KPMG Swiss tax specialists to inform them of new tax information received in the virtual data room as of 4/15/2020.	0.2	\$350	\$ 70.00
Devon Rowles	04/15/20	Updating the information request list to reflect comments from German specialists regarding the 2016 tax returns received as of 4/15/2020.	0.3	\$350	\$ 105.00
Danielle Moloughney	04/15/20	Call with S. Tyler (KPMG Canada), G. Bell (KPMG Canada), J. Lau (KPMG Canada), and D. Moloughney (KPMG Canada) to discuss draft cash tax model prepared by KPMG US for the contemplated disposition	0.4	\$172	\$ 68.80
Gregory Bell	04/15/20	Call with S. Tyler (KPMG Canada), G. Bell (KPMG Canada), J. Lau (KPMG Canada), and D. Moloughney (KPMG Canada) to discuss draft cash tax model prepared by KPMG US for the contemplated disposition	0.4	\$743	\$ 297.20

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Jonas Lau	04/15/20	Call with S. Tyler (KPMG Canada), G. Bell (KPMG Canada), J. Lau (KPMG Canada), and D. Moloughney (KPMG Canada) to discuss draft cash tax model prepared by KPMG US for the contemplated disposition	0.4	\$614	\$ 245.60
Sam Tyler	04/15/20	Call with S. Tyler (KPMG Canada), G. Bell (KPMG Canada), J. Lau (KPMG Canada), and D. Moloughney (KPMG Canada) to discuss draft cash tax model prepared by KPMG US for the contemplated disposition	0.4	\$743	\$ 297.20
Jess Commisso	04/15/20	Analyzed accumulated comments regarding cash tax model from local tax experts to determine what changes to make to the model as well as which jurisdictions we still need responses from.	0.6	\$350	\$ 210.00
Michael Land	04/15/20	Senior Associate review of updated profit & loss file in order with focus on potential change to our tax analysis with respect to certain dispositions	0.6	\$534	\$ 320.40
Danielle Moloughney	04/15/20	Review of draft cash tax model (from a Canadian tax perspective) prepared by KPMG US in preparation for upcoming call (same day).	0.7	\$172	\$ 120.40
Thomas Heubach	04/15/20	Finalize comments regarding cash tax model of the proposed disposal of a German entity provided by A. Armfield (KPMG US) after Partner review by C. Schmid (KPMG Germany)	0.8	\$653	\$ 522.40
Gavin Little	04/15/20	Performing managing director review of additional UK tax analysis drafted by M. Latham (KPMG UK) prior to its delivery to the KPMG US team.	1.0	\$985	\$ 985.00
Pete DiMatteo	04/15/20	Perform international tax manager review of PowerPoint presentation depicting UK proposed transactions / updates by local tax advisers - and concurrently revised (as needed).	1.1	\$650	\$ 715.00
Isaac Hirsch	04/15/20	Perform Managing Director review of updates to cash tax cost calculation for advice provided by local tax experts in Switzerland as of 4/15/2020.	1.1	\$819	\$ 900.90
Thomas Heubach	04/15/20	Reviewed newly uploaded tax documentation provided by D. Rowles (KPMG US) (1.0), draft email to D. Rowles regarding results of review (0.2)	1.2	\$653	\$ 783.60
Ashley Armfield	04/15/20	Continued, same day, updating cash tax model for updates to disposition scenarios based on review comments from managing director (2 countries)	1.3	\$534	\$ 694.20
Isaac Hirsch	04/15/20	Performed Managing Director review of updates to cash tax cost calculation for advice provided by local tax experts in Germany as of 4/15/2020.	1.3	\$819	\$ 1,064.70
Jess Commisso	04/15/20	Updates to the cash tax model for foreign tax consequences of Luxembourg ownership based on discussion with local tax experts.	1.6	\$350	\$ 560.00

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Isaac Hirsch	04/15/20	Performed Managing Director review of final updates to global structure deck for incorporation of comments from local country tax experts in the UK and Canada	2.3	\$819	\$ 1,883.70
Madeleine Latham	04/15/20	Updating the UK tax analysis based on review comments from G. Little (KPMG UK) to include in the structuring report prepared by KPMG US in response to KPMG US follow up questions regarding KPMG Italy input (sent last week).	2.8	\$343	\$ 943.25
Jess Commisso	04/15/20	(1.9) Review of newly received provided by client documentation in the virtual data room as of 4/15/2020 and (0.9) shared, via email, relevant information with KPMG Project team	2.8	\$350	\$ 980.00
Ashley Armfield	04/15/20	Updating cash tax model to include potential disposition of one United Kingdom entity as noted in structure deck.	2.9	\$534	\$ 1,548.60
Isaac Hirsch	04/15/20	(2.3) Performed Managing Director review of updates to US analysis portion of cash tax cost calculation in preparation of Washington National Tax review; (0.9) updates to cash tax cost calculation with regards to advice received from UK local tax experts.	3.2	\$819	\$ 2,620.80
Pete DiMatteo	04/15/20	Performed international tax manager review and concurrently revised PowerPoint presentation depicting contemplated dispositions of certain IACs to reflect comments related to local income taxes.	3.8	\$650	\$ 2,470.00
Ashley Armfield	04/15/20	Updating cash tax model for updates to disposition scenarios based on review comments from managing director (2 countries)	3.9	\$534	\$ 2,082.60
Sam Tyler	04/16/20	Drafted review comments to provide to J. Lau (KPMG Canada) to be incorporated into the model draft cash tax model prepared by KPMG US.	0.2	\$743	\$ 148.60
Dawn Krishnamurthy	04/16/20	Performed Manager review of Purdue IRL updates prepared by J. Commisso (KPMG).	0.2	\$695	\$ 139.00
Casey Nunez	04/16/20	Call between T. Stone (KPMG Washington National Tax) and I. Hirsch and C. Nunez (both KPMG) to discuss open information requests related to trusts and assumptions necessary to advance cash tax model.	0.4	\$744	\$ 297.60
Isaac Hirsch	04/16/20	Call between T. Stone (KPMG Washington National Tax) and I. Hirsch and C. Nunez (both KPMG) to discuss open information requests related to trusts and assumptions necessary to advance cash tax model.	0.4	\$819	\$ 327.60
Tracy Stone	04/16/20	Call between T. Stone (KPMG Washington National Tax) and I. Hirsch and C. Nunez (both KPMG) to discuss open information requests related to trusts and assumptions necessary to advance cash tax model.	0.4	\$906	\$ 362.40

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Zafer Ülgen	04/16/20	Draft e-mail describing measures taken by Dutch government to support business community in response to Covid-19 including how this could impact Dutch companies.	0.5	\$309	\$ 154.50
Claudio Mengotti	04/16/20	Performed initial high level Manager review of Swiss tax documents (uploaded to the data room as of 4/16/2020 - as indicated by D. Rowles from KPMG US) regarding potential Swiss tax aspects relevant for tax due diligence purposes.	0.5	\$610	\$ 305.00
Douglas Holland	04/16/20	Performed KPMG WNT Partner review of proposed disposition slides	0.6	\$985	\$ 591.00
Sam Tyler	04/16/20	Performed Partner level review of draft cash tax model prepared by KPMG US from a Canadian tax perspective.	0.6	\$743	\$ 445.80
Isaac Hirsch	04/16/20	Review of current version of information request list in preparation for upcoming call with advisors (UCC and Purdue legal and financial advisors)	0.6	\$819	\$ 491.40
Michael Land	04/16/20	Reviewed documentation uploaded to the data room as of $4/16/2020$ to identify / assess relevant tax information received.	0.6	\$534	\$ 320.40
Casey Nunez	04/16/20	Call with M. Hoffenberg (KPMG National Tax), H. Steinberg, I. Hirsch, and C. Nunez (all KPMG) to discuss status of information request list and open items necessary to advance cash tax modeling in preparation for call with PJT Partners, Province, Jeffries, and Alix Partners.	0.7	\$744	\$ 520.80
Howard Steinberg	04/16/20	Call with M. Hoffenberg (KPMG National Tax), H. Steinberg, I. Hirsch, and C. Nunez (all KPMG) to discuss status of information request list and open items necessary to advance cash tax modeling in preparation for call with PJT Partners, Province, Jeffries, and Alix Partners.	0.7	\$856	\$ 599.20
Isaac Hirsch	04/16/20	Call with M. Hoffenberg (KPMG National Tax), H. Steinberg, I. Hirsch, and C. Nunez (all KPMG) to discuss status of information request list and open items necessary to advance cash tax modeling in preparation for call with PJT Partners, Province, Jeffries, and Alix Partners.	0.7	\$819	\$ 573.30
Mark Hoffenberg	04/16/20	Call with M. Hoffenberg (KPMG National Tax), H. Steinberg, I. Hirsch, and C. Nunez (all KPMG) to discuss status of information request list and open items necessary to advance cash tax modeling in preparation for call with PJT Partners, Province, Jeffries, and Alix Partners.	0.7	\$980	\$ 686.00
Claudio Mengotti	04/16/20	Review of preliminary cash tax model (provided by KPMG US on April 15, 2020) with regards to Swiss tax consequences, such as withholding tax, capital gains tax, participation exemption in connection with potential restructuring options (asset sale versus stock sale) of Switzerland Mundipharma entities.	0.7	\$610	\$ 427.00

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Douglas Holland	04/16/20	Performed KPMG WNT Partner review and concurrently revise the proposed disposition slides for Netherlands	0.8	\$985	\$ 788.00
Jess Commisso	04/16/20	Review of latest version of the master structure deck to gain insight into both US and foreign tax consequences related to the disposition of Mundipharma entities.	0.8	\$350	\$ 280.00
Howard Steinberg	04/16/20	Call between M. Hoffenberg (KPMG National Tax), H. Steinberg, I. Hirsch, and C. Nunez (all KPMG) to discuss assumptions necessary to bridge the gap in missing information for cash tax model and advance cash tax modeling.	0.9	\$856	\$ 770.40
Mark Hoffenberg	04/16/20	Call between M. Hoffenberg (KPMG National Tax), H. Steinberg, I. Hirsch, and C. Nunez (all KPMG) to discuss assumptions necessary to bridge the gap in missing information for cash tax model and advance cash tax modeling.	0.9	\$980	\$ 882.00
Casey Nunez	04/16/20	Call between M. Hoffenberg (KPMG National Tax), H. Steinberg, I. Hirsch, and C. Nunez (all KPMG) to discuss assumptions necessary to bridge the gap in missing information for cash tax model and advance cash tax modeling.	0.9	\$744	\$ 669.60
Isaac Hirsch	04/16/20	Call between M. Hoffenberg (KPMG National Tax), H. Steinberg, I. Hirsch, and C. Nunez (all KPMG) to discuss assumptions necessary to bridge the gap in missing information for cash tax model and advance cash tax modeling.	0.9	\$819	\$ 737.10
Sayan Basak	04/16/20	Perform associate review of the cash tax model prepared by KPMG US and concurrently provide comments on the same.	0.9	\$124	\$ 111.60
Gregory Bell	04/16/20	Partner review draft cash tax model prepared by KPMG US for the contemplated disposition from a Canadian tax perspective.	1.0	\$743	\$ 743.00
Douglas Holland	04/16/20	Performed Principal Washington National Tax (WNT) review of slide deck for proposed German disposition and concurrently revised (as needed).	1.0	\$985	\$ 985.00
Ashley Armfield	04/16/20	Call with D. Holland, I. Hirsch, C. Nunez, A. Armfield, M. Land (all KPMG) to discuss the international tax considerations and assumptions contained in the KPMG cash tax model and next steps related to review tax associated with the disposition of a Canadian entity.	1.1	\$534	\$ 587.40
Casey Nunez	04/16/20	Call with D. Holland, I. Hirsch, C. Nunez, A. Armfield, M. Land (all KPMG) to discuss the international tax considerations and assumptions contained in the KPMG cash tax model and next steps related to review tax associated with the disposition of a Canadian entity.	1.1	\$744	\$ 818.40

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Douglas Holland	04/16/20	Call with D. Holland, I. Hirsch, C. Nunez, A. Armfield, M. Land (all KPMG) to discuss the international tax considerations and assumptions contained in the KPMG cash tax model and next steps related to review tax associated with the disposition of a Canadian entity.	1.1	\$985	\$ 1,083.50
Isaac Hirsch	04/16/20	Call with D. Holland, I. Hirsch, C. Nunez, A. Armfield, M. Land (all KPMG) to discuss the international tax considerations and assumptions contained in the KPMG cash tax model and next steps related to review tax associated with the disposition of a Canadian entity.	1.1	\$819	\$ 900.90
Michael Land	04/16/20	Call with D. Holland, I. Hirsch, C. Nunez, A. Armfield, M. Land (all KPMG) to discuss the international tax considerations and assumptions contained in the KPMG cash tax model and next steps related to review tax associated with the disposition of a Canadian entity.	1.1	\$534	\$ 587.40
Jonas Lau	04/16/20	Finalized comments from a Canadian tax perspective) on draft cash tax model prepared by KPMG US while concurrently noting assumptions to be added	1.1	\$614	\$ 675.40
Michael Land	04/16/20	Review of cash tax model for Canadian disposition scenarios in order to gain insight into cash flow.	1.1	\$534	\$ 587.40
Jess Commisso	04/16/20	(0.7) Review of newly received provided by client documentation in the virtual data room as of 4/16/2020 and (0.5) shared, via email, relevant information with KPMG Project team.	1.2	\$350	\$ 420.00
Casey Nunez	04/16/20	Meeting with I. Hirsch and C. Nunez (both KPMG) to discuss modeling updates necessary to prepare a preliminary calculations	1.2	\$744	\$ 892.80
Isaac Hirsch	04/16/20	Meeting with I. Hirsch and C. Nunez (both KPMG) to discuss modeling updates necessary to prepare a preliminary calculations	1.2	\$819	\$ 982.80
Jess Commisso	04/16/20	Updated the assumptions for the cash tax model based on results of discussion with local tax experts.	1.8	\$350	\$ 630.00
Pete DiMatteo	04/16/20	Performed international tax manager of structure extracts for additional jurisdictions to be included in tax cost calculation	2.1	\$650	\$ 1,365.00
Karl Tong	04/16/20	Review of certain tax information for Chinese entities in order to identify potential tax issues (1.8); Responded to email from D. Rowles (KPMG US) regarding tax key findings (0.3)	2.1	\$594	\$ 1,247.40
Isaac Hirsch	04/16/20	Review of most current version of the Purdue cash tax model in preparation for upcoming call with advisors (UCC and Purdue legal and financial advisors)	2.2	\$819	\$ 1,801.80

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Ashley Armfield	04/16/20	Update cash tax model to reflect potential disposition scenarios of United Kingdom entity pursuant to sending to United Kingdom tax specialist.	2.3	\$534	\$ 1,228.20
Ashley Armfield	04/16/20	Update cash tax model to reflect potential disposition scenarios of (another) United Kingdom entity pursuant to sending to United Kingdom tax specialist.	3.2	\$534	\$ 1,708.80
Ashley Armfield	04/16/20	Updated the Purdue cash tax model with regards to the income summary and allocation of funds from various entities, including the pass through of various Luxembourg structures.	3.5	\$534	\$ 1,869.00
Pete DiMatteo	04/16/20	Formulate listing of material open items in connection with US and foreign tax considerations relating to contemplated transactions.	3.8	\$650	\$ 2,470.00
Zafer Ülgen	04/17/20	Final review of changes made by L. van der Veen (KPMG Netherlands) with respect to e-mail describing measures taken by Dutch government to support business community in response to Covid-19, and how this could impact Dutch companies.	0.1	\$309	\$ 30.90
Douglas Holland	04/17/20	Draft email to KPMG Team and transmit revised slide deck with WNT Comments	0.2	\$985	\$ 197.00
Isaac Hirsch	04/17/20	Communication via email with D. Holland (KPMG WNT) regarding comments related to US tax analysis of hypothetical dispositions pursuant to the proposed settlement	0.3	\$819	\$ 245.70
Isaac Hirsch	04/17/20	Performed Managing Director review of comments from received from KPMG Canada, as of 4/17/2020, related cash tax modeling	0.4	\$819	\$ 327.60
Casey Nunez	04/17/20	Call between PJT Partners, Alix Partners, Jefferies, FTI Consulting, Houlihan Lokey, Brown Rudnick, Kramer Levin, and KPMG (M. Hoffenberg, H. Steinberg, I. Hirsch, and C. Nunez) to discuss progress on cash tax modeling and outstanding information needs as of 4/17/2020.	0.5	\$744	\$ 372.00
Howard Steinberg	04/17/20	Call between PJT Partners, Alix Partners, Jefferies, FTI Consulting, Houlihan Lokey, Brown Rudnick, Kramer Levin, and KPMG (M. Hoffenberg, H. Steinberg, I. Hirsch, and C. Nunez) to discuss progress on cash tax modeling and outstanding information needs as of 4/17/2020.	0.5	\$856	\$ 428.00
Isaac Hirsch	04/17/20	Call between PJT Partners, Alix Partners, Jefferies, FTI Consulting, Houlihan Lokey, Brown Rudnick, Kramer Levin, and KPMG (M. Hoffenberg, H. Steinberg, I. Hirsch, and C. Nunez) to discuss progress on cash tax modeling and outstanding information needs as of 4/17/2020.	0.5	\$819	\$ 409.50

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Mark Hoffenberg	04/17/20	Call between PJT Partners, Alix Partners, Jefferies, FTI Consulting, Houlihan Lokey, Brown Rudnick, Kramer Levin, and KPMG (M. Hoffenberg, H. Steinberg, I. Hirsch, and C. Nunez) to discuss progress on cash tax modeling and outstanding information needs as of 4/17/2020.	0.5	\$980	\$ 490.00
Aroen Rambhadjan	04/17/20	Partner review of e-mail drafted by L. van der Veen (KPMG Netherlands) in response to e-mail from I. Hirsch (KPMG); response provided further clarification of comments regarding cash tax model of potential disposal of Mundipharma DC BV.	0.5	\$884	\$ 442.00
Douglas Holland	04/17/20	Perform Principal Washington National Tax (WNT) review of proposed disposition Slides for Switzerland	0.5	\$985	\$ 492.50
Isaac Hirsch	04/17/20	Review documentation circulated by KPMG Germany regarding certain tax consequences of Intangible Property (IP) sale in relation to affect on cash tax modeling	0.6	\$819	\$ 491.40
Jess Commisso	04/17/20	(0.5) Reviewed newly received provided by client documentation in the virtual data room as of 4/17/2020 and (0.3) shared, via email, relevant information with KPMG Project team.	0.8	\$350	\$ 280.00
Lukas van der Veen	04/17/20	Manager review and concurrently amend e-mail describing measures taken by Dutch government to support business community in response to Covid-19, and how this could impact Dutch companies.	0.8	\$565	\$ 452.00
Lukas van der Veen	04/17/20	Respond to e-mail from I. Hirsh (KPMG US) regarding comments provided earlier on cash tax model describing consequences of proposed disposal a Dutch entity	0.8	\$565	\$ 452.00
Casey Nunez	04/17/20	Performed Senior Manager review of Evercore valuation file to facilitate valuation assumptions for disposition calculations.	0.9	\$744	\$ 669.60
Ashley Armfield	04/17/20	Call with D. Holland, I. Hirsch, C. Nunez, M. Land and A. Armfield (all KPMG) to review cash tax model considerations associated with six potential disposition scenarios (Switzerland, Germany and United Kingdom).	1.2	\$534	\$ 640.80
Casey Nunez	04/17/20	Call with D. Holland, I. Hirsch, C. Nunez, M. Land and A. Armfield (all KPMG) to review cash tax model considerations associated with six potential disposition scenarios (Switzerland, Germany and United Kingdom).	1.2	\$744	\$ 892.80
Isaac Hirsch	04/17/20	Call with D. Holland, I. Hirsch, C. Nunez, M. Land and A. Armfield (all KPMG) to review cash tax model considerations associated with six potential disposition scenarios (Switzerland, Germany and United Kingdom).	1.2	\$819	\$ 982.80
Douglas Holland	04/17/20	Call with D. Holland, I. Hirsch, C. Nunez, M. Land and A. Armfield (all KPMG) to review cash tax model considerations associated with six potential disposition scenarios (Switzerland, Germany and United Kingdom).	1.2	\$985	\$ 1,182.00

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Michael Land	04/17/20	Call with D. Holland, I. Hirsch, C. Nunez, M. Land and A. Armfield (all KPMG) to review cash tax model considerations associated with six potential disposition scenarios (Switzerland, Germany and United Kingdom).	1.2	\$534	\$ 640.80
Ashley Armfield	04/17/20	Reviewing comments provided by Canadian tax specialists with respect to the disposition assumptions and inputs around the Canadian disposition pursuant to preparing the cash tax model.	1.2	\$534	\$ 640.80
Douglas Holland	04/17/20	Perform Principal Washington National Tax (WNT) review of potential disposition Slides for UK Entities	1.5	\$985	\$ 1,477.50
Isaac Hirsch	04/17/20	Performed Managing Director review of revised model assumptions, that include more details, in preparation for broader circulation to Broader circulation to UCC and Purdue legal and financial advisors	1.7	\$819	\$ 1,392.30
Devon Rowles	04/17/20	Began to compare Evercore's valuation allocation analysis for the Mundipharma entities to previous provided by client information to ensure our understanding of material entities is aligned pursuant to creating a disposition structure deck and cash tax model for the material entities; please note: this is a very large task as financial statement for 127 Mundipharma entities had to be reviewed with regards to materiality of their assets/net profit in order to determine which jurisdictions KPMG would focus on.	1.9	\$350	\$ 665.00
Devon Rowles	04/17/20	Simultaneously reviewing and converting Evercore's valuation allocation analysis for the Mundipharma entities into a user-friendly excel version in preparation to provide to KPMG project team.	2.1	\$350	\$ 735.00
Pete DiMatteo	04/17/20	Performed international tax manager review of PowerPoint slides depicting contemplated Australian (0.9) and Chinese (1.3) dispositions.	2.2	\$650	\$ 1,430.00
Michael Land	04/17/20	Review of Purdue entity valuation summary provided by Evercore for purposes of determining additional entities necessary for disposition analysis	2.8	\$534	\$ 1,495.20
Pete DiMatteo	04/17/20	International tax manager formulation of structure extracts for additional jurisdictions to be included in tax cost calculation	3.4	\$650	\$ 2,210.00
Jess Commisso	04/17/20	Built out the proposed disposition steps for Australia (1.9 hours) and China (2.0 hours) Mundipharma entities within the master structure deck.	3.9	\$350	\$ 1,365.00
Michael Land	04/17/20	Preparation of summary to compare the Evercore model to our internal list of high priority jurisdictions for purposes of determining additional entities for which a disposition analysis is necessary	3.9	\$534	\$ 2,082.60

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Ashley Armfield	04/18/20	Updating cash tax model based on Dutch comments received, as of 4/18/2020, relating to disposition of Dutch entity.	1.5	\$534	\$ 801.00
Michael Land	04/18/20	Continue, from 4/17, preparation of summary to compare the Evercore model to our internal list of high priority jurisdictions for purposes of determining additional entities for which a disposition analysis is necessary	2.1	\$534	\$ 1,121.40
Ashley Armfield	04/18/20	Updating cash tax model to reflect sourcing to US entities with additional level of potential US taxes	2.1	\$534	\$ 1,121.40
Ashley Armfield	04/18/20	Updating cash tax model for Canadian tax specialist questions/ comments on cash tax model calculation - relating to the disposition of a Canadian entity.	2.8	\$534	\$ 1,495.20
Ashley Armfield	04/18/20	Updating the cash tax model with regards to German tax specialist commentary relating to the disposition of a German entity.	3.0	\$534	\$ 1,602.00
Devon Rowles	04/18/20	Continue (from previous day) comparison of Evercore's valuation allocation analysis for the Mundipharma entities to previous provided by client information (including financial statements and certain tax documentation) to ensure KPMG understanding of material entities is aligned pursuant to creating a disposition structure deck and cash tax model for the material entities; please note: this is a very large task as financial statement for 127 Mundipharma entities had to be reviewed with regards to materiality of their assets/net profit in order to determine which jurisdictions KPMG would focus on.	3.9	\$350	\$ 1,365.00
Ashley Armfield	04/19/20	Updating assumptions for calculation of United states taxation and foreign tax in the cash tax model relating to the US taxation on the proposed disposition of Mundipharma entities.	0.4	\$534	\$ 213.60
Devon Rowles	04/19/20	Continued (from 4/18) comparison of Evercore's valuation allocation analysis for the Mundipharma entities to previous provided by client information (including financial statements and certain tax documentation) to ensure KPMG understanding of material entities is aligned pursuant to creating a disposition structure deck and cash tax model for the material entities; please note: this is a very large task as financial statement for 127 Mundipharma entities had to be reviewed with regards to materiality of their assets/net profit in order to determine which jurisdictions KPMG would focus on.	1.6	\$350	\$ 560.00
Michael Land	04/19/20	Continued, from 4/18, to prepare summary to compare the Evercore model to our internal list of high priority jurisdictions for purposes of determining additional entities for which a disposition analysis is necessary	3.9	\$534	\$ 2,082.60

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Ashley Armfield	04/19/20	Continued, from earlier in day, to update Purdue cash tax model calculation of US federal income at the trust or individual level for all disposition scenarios.	3.9	\$534	\$ 2,082.60
Ashley Armfield	04/19/20	Updating the Purdue cash tax model calculation of US federal income at the trust or individual level for all disposition scenarios.	3.9	\$534	\$ 2,082.60
Claudio Mengotti	04/20/20	Compiled crucial information in connection with the cash tax model calculations provided by D. Rowles (KPMG US) pursuant to structuring report update as per April 8, 2020 concerning potential Swiss tax consequences	0.3	\$610	\$ 183.00
Ashley Armfield	04/20/20	Drafting email response to UK tax specialist relating to calculation in cash tax model.	0.3	\$534	\$ 160.20
Lukas van der Veen	04/20/20	Finalize e-mail to send to D. Rowles (KPMG US), including description of Dutch measures to support the business community during the Covid-19 crisis, and how these could be relevant for the Dutch Purdue companies.	0.3	\$565	\$ 169.50
Claudio Mengotti	04/20/20	Performed high level Manager review of additional Swiss tax documents (uploaded to the data room as indicated by D. Rowles from KPMG US as of 4/20/2020) regarding potential Swiss tax aspects relevant for tax due diligence purposes	0.5	\$610	\$ 305.00
Denis Larkin	04/20/20	Review of email received from H. Lewis (KPMG Australia) in respect of documentation uploaded to data room (0.1); performed Principal level review of documents (0.3); Performed Principal review and concurrently amend email prepared by H. Lewis to be sent to D. Rowles (KPMG US) (0.2).	0.6	\$566	\$ 339.60
Ashley Armfield	04/20/20	Call with D. Holland, I. Hirsch, and A. Armfield (all KPMG) to review and concurrently discuss cash tax model and the US and international tax considerations associated with four potential disposition scenarios (Singapore and Netherlands).	0.9	\$534	\$ 480.60
Douglas Holland	04/20/20	Call with D. Holland, I. Hirsch, and A. Armfield (all KPMG) to review and concurrently discuss cash tax model and the US and international tax considerations associated with four potential disposition scenarios (Singapore and Netherlands).	0.9	\$985	\$ 886.50
Isaac Hirsch	04/20/20	Call with D. Holland, I. Hirsch, and A. Armfield (all KPMG) to review and concurrently discuss cash tax model and the US and international tax considerations associated with four potential disposition scenarios (Singapore and Netherlands).	0.9	\$819	\$ 737.10
Sonia Stricker	04/20/20	Drafted email to I. Hirsch (KPMG US) regarding Intellectual Property (IP) used in Germany (0.6) and ownership structure in a German entity (0.3).	0.9	\$233	\$ 209.70
Isaac Hirsch	04/20/20	(1.0) Analyzed certain agreements provided by Norton Rose relating to historical supply chain for purposes of incorporating same into the cash tax model	1.0	\$819	\$ 819.00

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Paul Harden	04/20/20	Call with A. Desai (KPMG UK) to discuss the trust tax analysis (undertaken by P. Harden) ahead of calls with KPMG US this week.	1.0	\$985	\$ 985.00
Arpit Desai	04/20/20	Call with P. Harden (KPMG UK) to discuss the trust tax analysis (undertaken by P. Harden) ahead of calls with KPMG US this week.	1.0	\$750	\$ 750.00
Ashley Armfield	04/20/20	0.7 Draft detailed email to J. Commisso (KPMG) regarding cash tax model task to be completed relating to the allocation of potential foreign taxes; 0.4 Drafting email response to Canadian tax specialist relating to calculation in cash tax model.	1.1	\$534	\$ 587.40
Michael Land	04/20/20	Review of master structure deck (0.6) and preparation of additional Swiss entity in tax shapes for purposes of facilitating disposition analysis (0.5)	1.1	\$534	\$ 587.40
Ashley Armfield	04/20/20	Revised the Purdue cash tax model based on results of discussion with I. Hirsch and D. Holland (both KPMG).	1.1	\$534	\$ 587.40
Jess Commisso	04/20/20	(0.6) Reviewed newly received provided by client documentation in the virtual data room as of 4/20/2020 and (0.6) shared, via email, relevant information with KPMG Project team.	1.2	\$350	\$ 420.00
Hanah Lewis	04/20/20	Drafted summary of comments resulting from review of documentation sent by KPMG US (on same day) (1.0); drafted email to response to the KPMG US summarizing comments resulting from D. Larkin (KPMG Principal - Australia) review (0.5)	1.5	\$239	\$ 358.50
Marissa Low	04/20/20	Perform assistant manager review of the cash tax model/draft comments prepared by S. Basak (KPMG) from a Singapore tax perspective on the same.	1.5	\$247	\$ 370.50
Ashley Armfield	04/20/20	Discussion with I. Hirsch, C. Nunez, A. Armfield and J. Commisso (all KPMG) regarding incorporation of additional entities from high-priority jurisdiction into the cash tax model and which local experts to coordinate with pursuant to matching the model to the allocation of value within the Evercore valuation report provided by the client.	1.6	\$534	\$ 854.40
Casey Nunez	04/20/20	Discussion with I. Hirsch, C. Nunez, A. Armfield and J. Commisso (all KPMG) regarding incorporation of additional entities from high-priority jurisdiction into the cash tax model and which local experts to coordinate with pursuant to matching the model to the allocation of value within the Evercore valuation report provided by the client.	1.6	\$744	\$ 1,190.40

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Isaac Hirsch	04/20/20	Discussion with I. Hirsch, C. Nunez, A. Armfield and J. Commisso (all KPMG) regarding incorporation of additional entities from high-priority jurisdiction into the cash tax model and which local experts to coordinate with pursuant to matching the model to the allocation of value within the Evercore valuation report provided by the client.	1.6	\$819	\$ 1,310.40
Jess Commisso	04/20/20	Discussion with I. Hirsch, C. Nunez, A. Armfield and J. Commisso (all KPMG) regarding incorporation of additional entities from high-priority jurisdiction into the cash tax model and which local experts to coordinate with pursuant to matching the model to the allocation of value within the Evercore valuation report provided by the client.	1.6	\$350	\$ 560.00
Dawn Krishnamurthy	04/20/20	Discussion with I. Hirsch, P. DiMatteo, D. Krishnamurthy, M. Land and D. Rowles (all KPMG) regarding additional entities of high-priority jurisdiction to incorporate into structure deck through analysis of net profit amounts within the Evercore valuation provided by the client.	1.6	\$695	\$ 1,112.00
Devon Rowles	04/20/20	Discussion with I. Hirsch, P. DiMatteo, D. Krishnamurthy, M. Land and D. Rowles (all KPMG) regarding additional entities of high-priority jurisdiction to incorporate into structure deck through analysis of net profit amounts within the Evercore valuation provided by the client.	1.6	\$350	\$ 560.00
Isaac Hirsch	04/20/20	Discussion with I. Hirsch, P. DiMatteo, D. Krishnamurthy, M. Land and D. Rowles (all KPMG) regarding additional entities of high-priority jurisdiction to incorporate into structure deck through analysis of net profit amounts within the Evercore valuation provided by the client.	1.6	\$819	\$ 1,310.40
Michael Land	04/20/20	Discussion with I. Hirsch, P. DiMatteo, D. Krishnamurthy, M. Land and D. Rowles (all KPMG) regarding additional entities of high-priority jurisdiction to incorporate into structure deck through analysis of net profit amounts within the Evercore valuation provided by the client.	1.6	\$534	\$ 854.40
Pete DiMatteo	04/20/20	Discussion with I. Hirsch, P. DiMatteo, D. Krishnamurthy, M. Land and D. Rowles (all KPMG) regarding additional entities of high-priority jurisdiction to incorporate into structure deck through analysis of net profit amounts within the Evercore valuation provided by the client.	1.6	\$650	\$ 1,040.00
Michael Land	04/20/20	Updates to the summary of the of Evercore model based on feedback received from Managing Director as of 4/20.	1.9	\$534	\$ 1,014.60
Hanah Lewis	04/20/20	Review of specific tax information received from KPMG US related to an Australian entity per email request of D. Rowles (KPMG) (2.0)	2.0	\$239	\$ 478.00

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Isaac Hirsch	04/20/20	(1.2) Performed managing director review of allocation of valuation among IACs based on Evercore valuation report for purposes of determining material jurisdictions and preparing the cash tax model; (1.1) Performed managing director review of updates to global structure deck which incorporates China and Australia structures.	2.3	\$819	\$ 1,883.70
Pete DiMatteo	04/20/20	Perform an international tax manager review and concurrently revised the PowerPoint presentation depicting contemplated Israel dispositions, including US income tax considerations regarding same.	2.4	\$650	\$ 1,560.00
Pete DiMatteo	04/20/20	Perform international tax manager review and concurrently revised the PowerPoint presentation depicting contemplated Australian dispositions, including US income tax considerations regarding same.	2.4	\$650	\$ 1,560.00
Claudio Mengotti	04/20/20	Manager review and concurrently draft comments (in an e-mail) to send to KPMG US regarding cash tax model calculations provided by D. Rowles (KPMG US) pursuant to structuring report update as per April 8, 2020 concerning Swiss tax consequences.	2.5	\$610	\$ 1,525.00
Pete DiMatteo	04/20/20	Perform an international tax manager review and concurrently revised the PowerPoint presentation depicting contemplated Italian dispositions, including US income tax considerations regarding same.	2.8	\$650	\$ 1,820.00
Thomas Heubach	04/20/20	Perform Senior Manager review of certain data regarding information on Intellectual Property licensed to Mundipharma Germany or registered in Germany.	3.0	\$653	\$ 1,959.00
Jess Commisso	04/20/20	Revised the Purdue cash tax model to ensure proper breakout of certain potential tax (1.9) and consistency (1.2) throughout model	3.1	\$350	\$ 1,085.00
Ashley Armfield	04/20/20	Updated cash tax model summary results relating to US / non-US tax calculations to compare various scenarios relating to cash and tax cash flow.	3.1	\$534	\$ 1,655.40
Jess Commisso	04/20/20	Building out the disposition steps for Australia (1.6 hours) and China (1.6 hours) Mundipharma entities within the master structure deck.	3.2	\$350	\$ 1,120.00
Sonia Stricker	04/20/20	Review of certain data regarding information on Intellectual Property licensed to Mundipharma Germany or registered in Germany.	3.4	\$233	\$ 792.20

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Devon Rowles	04/20/20	Continued (from 4/19) comparison of Evercore's valuation allocation analysis for the Mundipharma entities to previous provided by client information (including financial statements and certain tax documentation) to ensure KPMG understanding of material entities is aligned pursuant to creating a disposition structure deck and cash tax model for the material entities; please note: this is a very large task as financial statement for 127 Mundipharma entities had to be reviewed with regards to materiality of their assets/net profit in order to determine which jurisdictions KPMG would focus on.	3.9	\$350	\$ 1,365.00
Michael Land	04/20/20	Finalized summary to compare the Evercore model to our internal list of high priority jurisdictions for purposes of determining additional entities for which a disposition analysis is necessary	3.9	\$534	\$ 2,082.60
Nicolas Meer	04/21/20	(0.1) Communication with D. Lipp (KPMG Switzerland) to discuss instructions to review the newly uploaded files in regard to the Swiss entities in detail and (0.2) based thereon, update the Swiss tax findings overview.	0.3	\$220	\$ 66.00
Claudio Mengotti	04/21/20	Implementation of remarks by S. Juon (Partner - KPMG Switzerland) into draft e-mail to provide to KPMG US regarding cash tax model calculations provided by D. Rowles (KPMG US) pursuant to structuring report update as per April 8, 2020 concerning Swiss tax consequences	0.4	\$610	\$ 244.00
Diego Lipp	04/21/20	Communication with N. Meer (KPMG Switzerland) to provide instruction regarding best approach to review the newly uploaded documentation the VDR (with regards to Swiss entities) and related updates the Swiss tax findings overview (with regards to findings related to review of same).	0.5	\$430	\$ 215.00
Simon Juon	04/21/20	Partner review of latest draft of email to KPMG US regarding cash tax model calculations provided by D. Rowles (KPMG US)	0.5	\$850	\$ 425.00
Ashley Armfield	04/21/20	Providing comments to email from C. Nunez (KPMG) relating to the assumptions KPMG is making with respect to the cash tax model and structuring deck (to be provided to KPMG Washington National tax team).	0.8	\$534	\$ 427.20
Michael Land	04/21/20	Review of certain agreements uploaded to the data room as of 4/21/20 for purposes of determining the economics therein to gain insight regarding potential cash flow consequences	0.8	\$534	\$ 427.20
Diego Lipp	04/21/20	Performed initial high level review of newly uploaded documentation in the virtual data room, as of 4/21/2020, in relation to the Swiss entities.	1.0	\$430	\$ 430.00
Michael Land	04/21/20	Preparation of a summary certain agreements for Italy to analyze if / when certain value was transferred	1.1	\$534	\$ 587.40

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Michael Land	04/21/20	Preparation of a summary certain agreements for the Netherlands to analyze if / when certain value was transferred	1.1	\$534	\$ 587.40
Claudio Mengotti	04/21/20	Manager review of draft email to send to KPMG US regarding cash tax model calculations provided by D. Rowles (KPMG US) pursuant to structuring report update as per April 8, 2020 concerning Swiss tax consequences.	1.2	\$610	\$ 732.00
Casey Nunez	04/21/20	Performed M&A tax senior manager review of certain agreements implicating cash tax modeling.	1.2	\$744	\$ 892.80
Casey Nunez	04/21/20	Drafted the trust-related assumptions necessary to move cash tax model forward	1.3	\$744	\$ 967.20
Mark Hoffenberg	04/21/20	Performed Principal Washington National tax review of certain agreements to consider tax treatment of obligations by Mundibiopharma to make supporting payments to related parties	1.4	\$980	\$ 1,372.00
Lukas van der Veen	04/21/20	Performed analysis related to treaty position of Luxembourg holding companies of a Dutch entity in case of certain distributions to its owner	1.6	\$565	\$ 904.00
Michael Land	04/21/20	2.1 Continued (same day) preparation of a summary of the preferred shares balance in order to gain insight into value and amount owed upon disposition	2.1	\$534	\$ 1,121.40
Ashley Armfield	04/21/20	Updating cash tax model for Luxembourg withholding taxes relating to the disposition of four entities.	2.1	\$534	\$ 1,121.40
Pete DiMatteo	04/21/20	Perform international tax manager review and concurrently revised the PowerPoint presentation depicting contemplated UK dispositions, including US income tax considerations regarding same.	2.6	\$650	\$ 1,690.00
Jess Commisso	04/21/20	Performed preliminary mapping (in excel) of overall structure of disposition entities and cash flow through the structure to ultimate trust beneficiaries pursuant to incorporating such structure into the cash tax model.	2.6	\$350	\$ 910.00
Devon Rowles	04/21/20	Created designated portion of structure decks for the disposition of Bermuda entities pursuant to illustrating the tax consequences of the disposition.	2.7	\$350	\$ 945.00
Pete DiMatteo	04/21/20	Performed international tax manager review and concurrently revised the PowerPoint presentation depicting contemplated Bermuda dispositions, including US income tax considerations related to same.	2.8	\$650	\$ 1,820.00
Ashley Armfield	04/21/20	2.9 Updating cash tax model to reflect allocation of income to US corporate entities as well as the additional layer of taxation associated with any potential distributions.	2.9	\$534	\$ 1,548.60

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Pete DiMatteo	04/21/20	Perform international tax manager review and concurrently revised the PowerPoint presentation depicting contemplated Dutch dispositions, including US income tax considerations related to same.	2.9	\$650	\$ 1,885.00
Ashley Armfield	04/21/20	3.2 Updating cash tax model summary of cash flow for all disposition scenarios to various trusts within the structure.	3.2	\$534	\$ 1,708.80
Jess Commisso	04/21/20	Building out the disposition steps for Israel (1.6) and Bermuda (1.6) Mundipharma entities within the master structure deck.	3.2	\$350	\$ 1,120.00
Isaac Hirsch	04/21/20	(0.8) Performed additional review / analysis of certain agreements relating to supply chain changes in relation to incorporation of same into cash tax model; (2.8) Performed Managing Director review of updates to cash tax model to incorporate advice received as of 4/21/2020 from local experts in Canada, Singapore, and Luxembourg, as well as advice from KPMG WNT.	3.6	\$819	\$ 2,948.40
Jess Commisso	04/21/20	Building out the disposition steps for Italy (1.6) and Korea (1.6) Mundipharma entities within the master structure deck; 0.6 Compilation of comments from local tax experts regarding the cash tax model pursuant to performing the appropriate updates to same.	3.8	\$350	\$ 1,330.00
Michael Land	04/21/20	3.9 Preparation of a summary of the preferred shares balance in order to gain insight into value / amount owed upon disposition	3.9	\$534	\$ 2,082.60
Devon Rowles	04/21/20	Created entity structures in tax shapes for various Mundipharma entities to illustrate the possible tax consequences of certain agreements between certain related parties	3.9	\$350	\$ 1,365.00
Ashley Armfield	04/22/20	Discussion with A. Armfield and D. Rowles (KPMG) regarding updates to be made to cash tax model relating to cash flow from all entity tabs.	0.4	\$534	\$ 213.60
Devon Rowles	04/22/20	Discussion with A. Armfield and D. Rowles (KPMG) regarding updates to be made to cash tax model relating to cash flow from all entity tabs.	0.4	\$350	\$ 140.00
Aroen Rambhadjan	04/22/20	Performed analysis related to treaty position of Luxembourg holding companies of a Dutch entity in case of certain distributions to its owner	0.5	\$884	\$ 442.00
Diego Lipp	04/22/20	Review of updates to Swiss tax findings overview as of 4/22/2020 - as prepared by N. Meer.	0.5	\$430	\$ 215.00

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Casey Nunez	04/22/20	Call into telephonic court hearing related to Purdue First Interim Applications as requested by counsel. KPMG Participants: H. Steinberg - Partner, I. Hirsch - International Managing Director, and C. Nunez Senior Manager - M&A Tax. The number of team members was necessary, due to the various work streams and inputs into the model, to ensure any potential concerns or issues were adequately addressed.	0.7	\$744	\$ 520.80
Howard Steinberg	04/22/20		0.7	\$856	\$ 599.20
Isaac Hirsch	04/22/20	Call into telephonic court hearing related to Purdue First Interim Applications as requested by counsel. KPMG Participants: H. Steinberg - Partner, I. Hirsch - International Managing Director, and C. Nunez Senior Manager - M&A Tax. The number of team members was necessary, due to the various work streams and inputs into the model, to ensure any potential concerns or issues were adequately addressed.	0.7	\$819	\$ 573.30
Ashley Armfield	04/22/20	Call with D. Holland, I. Hirsch, C. Nunez, and A. Armfield (all KPMG) to discuss review of cash tax model and the US tax calculations for corporate entities within the Company's structure	0.9	\$534	\$ 480.60
Casey Nunez	04/22/20	Call with D. Holland, I. Hirsch, C. Nunez, and A. Armfield (all KPMG) to discuss review of cash tax model and the US tax calculations for corporate entities within the Company's structure	0.9	\$744	\$ 669.60
Douglas Holland	04/22/20	Call with D. Holland, I. Hirsch, C. Nunez, and A. Armfield (all KPMG) to discuss review of cash tax model and the US tax calculations for corporate entities within the Company's structure	0.9	\$985	\$ 886.50
Isaac Hirsch	04/22/20	Call with D. Holland, I. Hirsch, C. Nunez, and A. Armfield (all KPMG) to discuss review of cash tax model and the US tax calculations for corporate entities within the Company's structure	0.9	\$819	\$ 737.10
Ashley Armfield	04/22/20	Call with M. Land and A. Armfield (KPMG) to discuss the impact of preferred equity agreements between certain mundipharma entities and the relevant impact on cash tax modeling.	0.9	\$534	\$ 480.60

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Michael Land	04/22/20	Call with M. Land and A. Armfield (KPMG) to discuss the impact of preferred equity agreements between certain mundipharma entities and the relevant impact on cash tax modeling.	0.9	\$534	\$ 480.60
Devon Rowles	04/22/20	Email correspondence with KPMG member firms Korea, Switzerland, Netherlands, Australian and China tax specialists (concurrently) regarding next steps related to upcoming call to discuss the structure deck and cash tax model of the disposition entities	0.9	\$350	\$ 315.00
Gordon Lawson	04/22/20	Performed Partner review of the cash tax model and concurrently draft comments from a Singapore tax perspective on the same	1.0	\$791	\$ 791.00
Devon Rowles	04/22/20	Concurrently updated the information request list and virtual data room tracker based on new documentation provided by client as of 4/22/20 - pursuant to communicating updates/outstanding items to KPMG project team.	1.1	\$350	\$ 385.00
Devon Rowles	04/22/20	Continue (from previous day) to created entity structures in tax shapes for various Mundipharma entities to illustrate the possible tax consequences of certain agreements between certain related parties	1.1	\$350	\$ 385.00
Michael Land	04/22/20	Reviewed Netherlands entity financial statements in order to gain insight into capital structure	1.1	\$534	\$ 587.40
Jess Commisso	04/22/20	Coordination with assigned portion of tax experts (6 different KPMG member firms) regarding next steps related to discussion regarding the local tax implications for the structure deck and cash tax model.	1.2	\$350	\$ 420.00
Claudio Mengotti	04/22/20	Drafted detailed email to address comments / additional questions from I. Hirsch (KPMG US) in connection with Swiss cash tax model aspects as per calculation provided by D. Rowles (KPMG US) pursuant to structuring report update as per April 8, 2020 concerning potential Swiss tax consequences	1.2	\$610	\$ 732.00
Michael Land	04/22/20	Review of Singapore entity financial statements in order to gain insight into capital structure	1.3	\$534	\$ 694.20
Jess Commisso	04/22/20	Revised the Purdue cash tax model based on review comments received from I. Hirsch (KPMG Managing Director) on 4/22/20.	1.3	\$350	\$ 455.00
Thomas Heubach	04/22/20	Draft detailed email to I. Hirsch (KPMG US) on ownership structure in Germany that includes an discussion on the types (and rights thereto) of shares	1.4	\$653	\$ 914.20
Michael Land	04/22/20	Review of Finland entity financial statements in order to gain insight into capital structure	1.4	\$534	\$ 747.60
Michael Land	04/22/20	Review of Norway entity financial statements in order to gain insight into capital structure	1.4	\$534	\$ 747.60

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Aroen Rambhadjan	04/22/20	Partner level review of Dutch tax consequences of transfer of certain functions to a related party	1.5	\$884	\$ 1,326.00
Christian Schmid	04/22/20	Perform Partner review of draft email to I. Hirsch (KPMG US), initially prepared by T. Heubach (KPMG Germany) on certain intellectual property held abroad (0.8) and ownership structure in German structure (0.2) as well as review of potential German tax consequences (0.6).	1.6	\$817	\$ 1,307.20
Roger Lee	04/22/20	Perform manager review of the cash tax model along with draft comments (prepared by S. Basak -KPMG) from a Singapore tax perspective with focus on certain redemptions	2.0	\$371	\$ 742.00
Isaac Hirsch	04/22/20	Performed Managing director review of most recent updates to cash tax model for revisions to reflect certain agreements provided by Norton Rose	2.2	\$819	\$ 1,801.80
Michael Land	04/22/20	Review of Spain entity financial statements in order to gain insight into capital structure	2.2	\$534	\$ 1,174.80
Lukas van der Veen	04/22/20	Manager level review of Dutch tax consequences of transfer of certain functions to a related party	2.4	\$565	\$ 1,356.00
Jess Commisso	04/22/20	Review of local tax experts cash tax model commentary as of 4/22/2020 to ensure all assumptions are being captured in the model.	2.5	\$350	\$ 875.00
Pete DiMatteo	04/22/20	Perform international tax manager review and concurrently revised the PowerPoint presentation depicting contemplated Korea dispositions, including US income tax considerations regarding same.	2.8	\$650	\$ 1,820.00
Nicolas Meer	04/22/20	Review of newly uploaded documentation in the VDR in regard to the Swiss entities in detail and based thereon, concurrently update the Swiss tax findings overview as requested by D. Lipp (KPMG Switzerland)	2.8	\$220	\$ 616.00
Pete DiMatteo	04/22/20	Performed international tax manager review and concurrently revised the PowerPoint presentation depicting contemplate Dutch dispositions, including US income tax considerations regarding same.	3.1	\$650	\$ 2,015.00
Devon Rowles	04/22/20	Revised the Purdue cash tax model with regards to senior associate review comments received as of 4/22/2020.	3.4	\$350	\$ 1,190.00
Thomas Heubach	04/22/20	Drafted information to be provided to I. Hirsch (KPMG US) via email regarding certain intellectual property maintained abroad and potential German tax consequences resulting therefrom.	3.6	\$653	\$ 2,350.80
Ashley Armfield	04/22/20	Updating cash tax model based on director review - in order to reflect changes to cash flow organization for all entities (2.8) and calculation of corporate income taxes (0.8).	3.6	\$534	\$ 1,922.40

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Lukas van der Veen	04/23/20	Performed Manager level review of certain agreements provided by M. Land (KPMG US) (from a Dutch tax perspective) in preparation of the call held April 23, 2020 with I. Hirsch, P. DiMatteo (KPMG US) and A. Rambhadjan (KPMG Netherlands).	0.3	\$565	\$ 169.50
Lukas van der Veen	04/23/20	Manager level review of slides on proposed disposal of a Dutch entity provided by P. DiMatteo (KPMG US) in preparation of the call held April 23, 2020 with I. Hirsch, P. DiMatteo (KPMG US) and A. Rambhadjan (KPMG Netherlands).	0.4	\$565	\$ 226.00
Diego Lipp	04/23/20	Call with C. Mengotti (KPMG Switzerland) to discuss Swiss tax findings and related information to be included in email to D. Rowles (KPMG US) regarding same.	0.5	\$430	\$ 215.00
Claudio Mengotti	04/23/20	Call with D. Lipp (KPMG Switzerland) to discuss Swiss tax findings and related information to be included in email to D. Rowles (KPMG US) regarding same.	0.5	\$610	\$ 305.00
Aroen Rambhadjan	04/23/20	Performed Partner level review of slide documentation on proposed disposal of a Dutch entity provided by P. DiMatteo (KPMG US) in preparation of the call held April 23, 2020 with I. Hirsch, P. DiMatteo (KPMG US) and L. van der Veen (KPMG Netherlands).	0.5	\$884	\$ 442.00
Aroen Rambhadjan	04/23/20	Perform Partner level review of certain agreements (from a Dutch tax perspective) provided by M. Land (KPMG US) in preparation of the call held April 23, 2020 with I. Hirsch, P. DiMatteo (KPMG US) and L. van der Veen (KPMG Netherlands).	0.7	\$884	\$ 618.80
Diego Lipp	04/23/20	Prepare email to D. Rowles (KPMG US) to share update on Swiss tax findings based on recently uploaded tax information.	1.0	\$430	\$ 430.00
Diego Lipp	04/23/20	Senior Associate review of revised version of Swiss tax findings overview, as of 4/23/2020 - as prepared by N. Meer (KPMG Switzerland)	1.0	\$430	\$ 430.00
Lukas van der Veen	04/23/20	Performed additional analysis to determine whether Dutch Purdue companies would be eligible to claim certain benefits with respect to potential distributions	1.1	\$565	\$ 621.50
Lukas van der Veen	04/23/20	Conference call with I. Hirsch, P. DiMatteo (KPMG US), A. Rambhadjan, L. van der Veen (KPMG Netherlands) to discuss certain agreements, structuring, and Dutch tax considerations associated with contemplated disposition sales with respect to a Dutch Mundipharma entity	1.3	\$565	\$ 734.50

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Aroen Rambhadjan	04/23/20	Conference call with I. Hirsch, P. DiMatteo (KPMG US), A. Rambhadjan, L. van der Veen (KPMG Netherlands) to discuss certain agreements, structuring, and Dutch tax considerations associated with contemplated disposition sales with respect to a Dutch Mundipharma entity	1.3	\$884	\$ 1,149.20
Isaac Hirsch	04/23/20	Conference call with I. Hirsch, P. DiMatteo (KPMG US), A. Rambhadjan, L. van der Veen (KPMG Netherlands) to discuss certain agreements, structuring, and Dutch tax considerations associated with contemplated disposition sales with respect to a Dutch Mundipharma entity	1.3	\$819	\$ 1,064.70
Pete DiMatteo	04/23/20	Conference call with I. Hirsch, P. DiMatteo (KPMG US), A. Rambhadjan, L. van der Veen (KPMG Netherlands) to discuss certain agreements, structuring, and Dutch tax considerations associated with contemplated disposition sales with respect to a Dutch Mundipharma entity	1.3	\$650	\$ 845.00
Devon Rowles	04/23/20	Continued (same day) to review the cash tax model in tandem with the structure deck to verify that they two deliverables are aligned, specifically with respect to cash tax implications related to the disposition of various Mundipharma entities	1.4	\$350	\$ 490.00
Michael Land	04/23/20	Review of Portugal entity financial statements in order to gain insight into capital structure	1.4	\$534	\$ 747.60
Michael Land	04/23/20	Review of Swedish entity financial statements in order to gain insight into capital structure	1.4	\$534	\$ 747.60
Michael Land	04/23/20	Review of Switzerland entity financial statements in order to gain insight into capital structure	1.4	\$534	\$ 747.60
Michael Land	04/23/20	Review of South Africa entity financial statements in order to gain insight into capital structure	1.6	\$534	\$ 854.40
Devon Rowles	04/23/20	Review of Netherlands structure deck as well as related cash flow in order to gain insight into Netherlands tax consequences resulting from KPMG US management's call with Dutch tax specialists	1.7	\$350	\$ 595.00
Michael Land	04/23/20	Reviewed UK entity financial statements with focus on gaining insight into capital structure	1.7	\$534	\$ 907.80
Michael Land	04/23/20	Reviewed Italy entity financial statements with focus on gaining insight into capital structure	1.9	\$534	\$ 1,014.60
Claudio Mengotti	04/23/20	Continued (from 4/20) to perform high level Manager review of additional Swiss tax documents (uploaded to the data room as indicated by D. Rowles from KPMG US) regarding potential Swiss tax aspects relevant for high level tax due diligence purposes (1.3) and drafted respective e-mail to KPMG US on April 23 regarding potential Swiss withholding tax issues (0.9)	2.2	\$610	\$ 1,342.00

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Jess Commisso	04/23/20	Created flowchart of how the cash tax model is set up for purposes of simpler explanation and understanding in preparation for presentation to the client.	2.3	\$350	\$ 805.00
Ashley Armfield	04/23/20	Revise the Purdue cash tax model with regards to comments received from KPMG Swiss (1.6) and KPMG Netherlands (0.8) tax specialists.	2.4	\$534	\$ 1,281.60
Pete DiMatteo	04/23/20	Perform international tax manager review and concurrently revised the PowerPoint presentation depicting contemplated UK transactions (with related parties), including US income tax considerations regarding same.	2.9	\$650	\$ 1,885.00
Jess Commisso	04/23/20	Review of my assigned portion of high-priority jurisdictions in the cash tax model to ensure accuracy of calculations and maintaining consistency.	2.9	\$350	\$ 1,015.00
Jess Commisso	04/23/20	Review of US tax calculation / income summary tabs in the cash tax model to ensure accuracy in the calculations and maintaining consistency.	2.9	\$350	\$ 1,015.00
Pete DiMatteo	04/23/20	Perform international tax manager review and concurrently revised the PowerPoint presentation depicting contemplated UK transactions (with additional related parties), including US income tax considerations regarding same.	3.3	\$650	\$ 2,145.00
Isaac Hirsch	04/23/20	(0.6) Communication via email with M. Hoffenberg and D. Holland (both KPMG Washington National Tax) regarding the allocation of income for purposes of the cash tax model; (2.9) Performed Managing Director review of updates to cash tax model to incorporate analysis of potential deductions	3.5	\$819	\$ 2,866.50
Devon Rowles	04/23/20	Review the cash tax model in tandem with the structure deck to verify that they two deliverables are aligned, specifically with respect to cash tax implications related to the disposition of various Mundipharma entities	3.9	\$350	\$ 1,365.00
Ashley Armfield	04/23/20	Senior Associate review of comments / proposed updates to six disposition scenarios (including three different jurisdictions) prepared by D. Rowles (KPMG)	3.9	\$534	\$ 2,082.60
Ashley Armfield	04/23/20	Updating cash tax model to reflect adjustments to the potential circular flow of cash based on implementation of certain payments.	3.9	\$534	\$ 2,082.60
Ashley Armfield	04/23/20	Updating cash tax model to reflect the flow of cash taxes through four US disposition entities based on discussions with I. Hirsch and D. Holland (breaking out cash flow between all trusts).	3.9	\$534	\$ 2,082.60
Lorenzo Bellavite	04/24/20	Performed Partner review of the email response to M. Land (KPMG US) - prepared by C. Bertù (KPMG Italy) detailing results of review of available documents.	0.2	\$476	\$ 95.20

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Carlotta Bertu	04/24/20	Review of specific tax information related to an Italian entity to answer the questions asked by M. Land (KPMG US) with regards to email received dated April 21, 2020.	0.4	\$214	\$ 85.60
Simon Juon	04/24/20	Partner review of proposed structuring options with regard to potential sale of Mundipharma entities and subsequent repatriation of funds with focus on Swiss structuring comments to be included into the KPMG US structuring slides.	0.5	\$850	\$ 425.00
Claudio Mengotti	04/24/20	Manager review of proposed structuring options with regard to potential sale of Mundipharma entities and subsequent repatriation of funds with focus on Swiss structuring comments to be included into the KPMG US structuring slides.	0.5	\$610	\$ 305.00
Jess Commisso	04/24/20	Updated the assumptions for the Singapore disposition entity as per local tax experts commentary received as of 4/24/2020.	0.6	\$350	\$ 210.00
Claudio Mengotti	04/24/20	Performed initial high level Manager review of structuring suggestions in connection with a potential disposition in order to derive potential material Swiss tax aspects to be discussed during call with KPMG US team on April 24, 2020	0.7	\$610	\$ 427.00
Claudio Mengotti	04/24/20	Preparation of appropriate language in connection with uncertainty of Swiss capital contribution reserves and related potential withholding tax aspects - as requested by I. Hirsch (KPMG US)	0.7	\$610	\$ 427.00
Ashley Armfield	04/24/20	Call with I. Hirsch and A. Armfield (both KPMG) to discuss cash tax model updates that need to be performed relating to non-US taxation imposed as a result of the Mundipharma dispositions.	0.8	\$534	\$ 427.20
Isaac Hirsch	04/24/20	Call with I. Hirsch and A. Armfield (both KPMG) to discuss cash tax model updates that need to be performed relating to non-US taxation imposed as a result of the Mundipharma dispositions.	0.8	\$819	\$ 655.20
Paul Harden	04/24/20	Discussion with I. Hirsch, C. Nunez, G. Little, P. Harden, A. Desai, and M. Latham (all KPMG) regarding UK tax treatment of certain payments to properly reflecting such rates in the cash tax model.	0.8	\$985	\$ 788.00
Gavin Little	04/24/20	Discussion with I. Hirsch, C. Nunez, G. Little, P. Harden, A. Desai, and M. Latham (all KPMG) regarding UK tax treatment of certain payments to properly reflecting such rates in the cash tax model.	0.8	\$985	\$ 788.00
Arpit Desai	04/24/20	Discussion with I. Hirsch, C. Nunez, G. Little, P. Harden, A. Desai, and M. Latham (all KPMG) regarding UK tax treatment of certain payments to properly reflecting such rates in the cash tax model.	0.8	\$750	\$ 600.00

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Madeleine Latham	04/24/20	Discussion with I. Hirsch, C. Nunez, G. Little, P. Harden, A. Desai, and M. Latham (all KPMG) regarding UK tax treatment of certain payments to properly reflecting such rates in the cash tax model.	0.8	\$343	\$ 274.40
Casey Nunez	04/24/20	Discussion with I. Hirsch, C. Nunez, G. Little, P. Harden, A. Desai, and M. Latham (all KPMG) regarding UK tax treatment of certain payments to properly reflecting such rates in the cash tax model.	0.8	\$744	\$ 595.20
Isaac Hirsch	04/24/20	Discussion with I. Hirsch, C. Nunez, G. Little, P. Harden, A. Desai, and M. Latham (all KPMG) regarding UK tax treatment of certain payments to properly reflecting such rates in the cash tax model.	0.8	\$819	\$ 655.20
Mark Hoffenberg	04/24/20	Draft email to KPMG project team regarding consistency between allocation of trust proceeds among beneficiaries and potential deductions.	0.8	\$980	\$ 784.00
Claudio Mengotti	04/24/20	Conference call with I. Hirsch, C. Nunez, P. DiMatteo (KPMG US) and S. Juon, C. Mengotti (KPMG Switzerland) to discuss structuring, cash tax model, and Swiss tax considerations associated with contemplated dispositions with respect to various Swiss Mundipharma entities.	0.9	\$610	\$ 549.00
Simon Juon	04/24/20	Conference call with I. Hirsch, C. Nunez, P. DiMatteo (KPMG US) and S. Juon, C. Mengotti (KPMG Switzerland) to discuss structuring, cash tax model, and Swiss tax considerations associated with contemplated dispositions with respect to various Swiss Mundipharma entities.	0.9	\$850	\$ 765.00
Casey Nunez	04/24/20	Conference call with I. Hirsch, C. Nunez, P. DiMatteo (KPMG US) and S. Juon, C. Mengotti (KPMG Switzerland) to discuss structuring, cash tax model, and Swiss tax considerations associated with contemplated dispositions with respect to various Swiss Mundipharma entities.	0.9	\$744	\$ 669.60
Isaac Hirsch	04/24/20	Conference call with I. Hirsch, C. Nunez, P. DiMatteo (KPMG US) and S. Juon, C. Mengotti (KPMG Switzerland) to discuss structuring, cash tax model, and Swiss tax considerations associated with contemplated dispositions with respect to various Swiss Mundipharma entities.	0.9	\$819	\$ 737.10
Pete DiMatteo	04/24/20	Conference call with I. Hirsch, C. Nunez, P. DiMatteo (KPMG US) and S. Juon, C. Mengotti (KPMG Switzerland) to discuss structuring, cash tax model, and Swiss tax considerations associated with contemplated dispositions with respect to various Swiss Mundipharma entities.	0.9	\$650	\$ 585.00
Isaac Hirsch	04/24/20	Performed Managing Director review of preferred stock analysis for purposes of incorporation in the cash tax model	1.2	\$819	\$ 982.80

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Devon Rowles	04/24/20	Review of Swiss structure deck along with related cash flow in order to gain insight into Swiss tax consequences resulting from KPMG US management's call with Swiss tax specialists	1.3	\$350	\$ 455.00
Isaac Hirsch	04/24/20	Prepare for upcoming calls with KPMG Switzerland and KPMG UK, by reviewing global cash tax model (0.8) and global structure deck (0.6).	1.4	\$819	\$ 1,146.60
Michael Land	04/24/20	Review of Belgium entity financial statements for with focus on gaining insight into capital structure	1.5	\$534	\$ 801.00
Michael Land	04/24/20	1.6 Review of France entity financial statements in order to gain insight into capital structure	1.6	\$534	\$ 854.40
Ashley Armfield	04/24/20	Discussion with A. Armfield, D. Rowles and J. Commisso (all KPMG) regarding the set-up and flow of the cash tax model pursuant to performing appropriate updates.	1.7	\$534	\$ 907.80
Devon Rowles	04/24/20	Discussion with A. Armfield, D. Rowles and J. Commisso (all KPMG) regarding the set-up and flow of the cash tax model pursuant to performing appropriate updates.	1.7	\$350	\$ 595.00
Jess Commisso	04/24/20	Discussion with A. Armfield, D. Rowles and J. Commisso (all KPMG) regarding the set-up and flow of the cash tax model pursuant to performing appropriate updates.	1.7	\$350	\$ 595.00
Jess Commisso	04/24/20	Revised the model flowchart (how the cash tax model is set up for purposes of simpler explanation and understanding) to match most recent model updates.	1.7	\$350	\$ 595.00
Pete DiMatteo	04/24/20	Performed, as of 4/24/2020, an international tax manager review and concurrently revised the latest version of the structure deck depicting various contemplated distributions from certain entities.	1.9	\$650	\$ 1,235.00
Pete DiMatteo	04/24/20	Perform, as of 4/24/2020, international tax manager review and concurrently revised the Purdue structure deck depicting various transactions.	2.1	\$650	\$ 1,365.00
Isaac Hirsch	04/24/20	Review updates to global cash tax model to incorporate advice from WNT on US cash tax consequences.	2.2	\$819	\$ 1,801.80
Casey Nunez	04/24/20	Performed M&A senior manager review of updated cash tax model structure, as of 4/24/2020, to ensure accuracy.	2.6	\$744	\$ 1,934.40
Ashley Armfield	04/24/20	Revisions to cash tax model with respect to centralizing the cash tax options with respect to the model inputs and assumptions.	3.7	\$534	\$ 1,975.80
Michael Land	04/24/20	3.9 Preparation of a summary of the preferred shares balance in order to gain insight into value / amount owed upon disposition.	3.9	\$534	\$ 2,082.60

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Devon Rowles	04/24/20	Created structure deck for various Mundipharma entities to illustrate the possible tax consequences / related cash flow of certain agreements between Mundibiopharma and related parties	3.9	\$350	\$ 1,365.00
Ashley Armfield	04/26/20	Updated the Purdue cash tax model tax calculation for United States individuals and trusts based on comments received from director as of 4/26/2020.	2.1	\$534	\$ 1,121.40
Robin Lijzenga	04/27/20	Manager level review (from a Luxembourg tax perspective) of the second additional slide deck provided by the U.S. team regarding the Mundipharma Disposition Analysis	0.2	\$730	\$ 146.00
Emilien Lebas	04/27/20	Partner review of the second additional slide deck provided by the U.S. team regarding the Mundipharma Disposition Analysis	0.2	\$985	\$ 197.00
Alejandro Merelles Rodriguez	04/27/20	Senior Associate level review of the second additional slide deck provided by the U.S. team regarding the Mundipharma Disposition Analysis	0.2	\$640	\$ 128.00
Robin Lijzenga	04/27/20	Manager level review (from a Luxembourg tax perspective) of the first additional slide deck provided by the U.S. team regarding the Mundipharma Disposition Analysis (i.e. the Additional Jurisdictions slide deck)	0.3	\$730	\$ 219.00
Emilien Lebas	04/27/20	Partner review of the first additional slide deck provided by the U.S. team regarding the Mundipharma Disposition Analysis (i.e. the Additional Jurisdictions slide deck)	0.3	\$985	\$ 295.50
Alejandro Merelles Rodriguez	04/27/20	Senior Associate level review of the first additional slide deck provided by the U.S. team regarding the Mundipharma Disposition Analysis (i.e. the Additional Jurisdictions slide deck)	0.3	\$640	\$ 192.00
Emilien Lebas	04/27/20	Discussion with I. Hirsch, P. DiMatteo, A. Armfield (KPMG US) and E. Lebas, and R. Lijzenga (KPMG Luxembourg) regarding Luxembourg tax consequences related to distributions of preferred equity within Mundipharma structures pursuant to applying the appropriate rates in the structure deck and cash tax model.	0.4	\$985	\$ 394.00
Robin Lijzenga	04/27/20	Discussion with I. Hirsch, P. DiMatteo, A. Armfield (KPMG US) and E. Lebas, and R. Lijzenga (KPMG Luxembourg) regarding Luxembourg tax consequences related to distributions of preferred equity within Mundipharma structures pursuant to applying the appropriate rates in the structure deck and cash tax model.	0.4	\$730	\$ 292.00

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Ashley Armfield	04/27/20	Discussion with I. Hirsch, P. DiMatteo, A. Armfield (KPMG US) and E. Lebas, and R. Lijzenga (KPMG Luxembourg) regarding Luxembourg tax consequences related to distributions of preferred equity within Mundipharma structures pursuant to applying the appropriate rates in the structure deck and cash tax model.	0.4	\$534	\$ 213.60
Isaac Hirsch	04/27/20	Discussion with I. Hirsch, P. DiMatteo, A. Armfield (KPMG US) and E. Lebas, and R. Lijzenga (KPMG Luxembourg) regarding Luxembourg tax consequences related to distributions of preferred equity within Mundipharma structures pursuant to applying the appropriate rates in the structure deck and cash tax model.	0.4	\$819	\$ 327.60
Pete DiMatteo	04/27/20	Discussion with I. Hirsch, P. DiMatteo, A. Armfield (KPMG US) and E. Lebas, and R. Lijzenga (KPMG Luxembourg) regarding Luxembourg tax consequences related to distributions of preferred equity within Mundipharma structures pursuant to applying the appropriate rates in the structure deck and cash tax model.	0.4	\$650	\$ 260.00
Ashley Armfield	04/27/20	Conference call between M. Hoffenberg and T. Stone (both KPMG Washington National Tax) and I. Hirsch, C. Nunez, and A. Armfield (KPMG) to discuss overlap of trust rules, potential deductions available, and modeling scenarios.	0.5	\$534	\$ 267.00
Casey Nunez	04/27/20	Conference call between M. Hoffenberg and T. Stone (both KPMG Washington National Tax) and I. Hirsch, C. Nunez, and A. Armfield (KPMG) to discuss overlap of trust rules, potential deductions available, and modeling scenarios.	0.5	\$744	\$ 372.00
Isaac Hirsch	04/27/20	Conference call between M. Hoffenberg and T. Stone (both KPMG Washington National Tax) and I. Hirsch, C. Nunez, and A. Armfield (KPMG) to discuss overlap of trust rules, potential deductions available, and modeling scenarios.	0.5	\$819	\$ 409.50
Mark Hoffenberg	04/27/20	Conference call between M. Hoffenberg and T. Stone (both KPMG Washington National Tax) and I. Hirsch, C. Nunez, and A. Armfield (KPMG) to discuss overlap of trust rules, potential deductions available, and modeling scenarios.	0.5	\$980	\$ 490.00
Tracy Stone	04/27/20	Conference call between M. Hoffenberg and T. Stone (both KPMG Washington National Tax) and I. Hirsch, C. Nunez, and A. Armfield (KPMG) to discuss overlap of trust rules, potential deductions available, and modeling scenarios.	0.5	\$906	\$ 453.00
Casey Nunez	04/27/20	Meeting between I. Hirsch, C. Nunez, and A. Armfield (all KPMG) to discuss status of cash tax modeling and next steps as of 4/27/2020.	0.5	\$744	\$ 372.00

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Isaac Hirsch	04/27/20	Meeting between I. Hirsch, C. Nunez, and A. Armfield (all KPMG) to discuss status of cash tax modeling and next steps as of 4/27/2020.	0.5	\$819	\$ 409.50
Ashley Armfield	04/27/20	Meeting between I. Hirsch, C. Nunez, and A. Armfield (all KPMG) to discuss status of cash tax modeling and next steps as of 4/27/2020.	0.5	\$534	\$ 267.00
Casey Nunez	04/27/20	0.6 Performed M&A Senior Manager review of latest version of cash tax model flow chart.	0.6	\$744	\$ 446.40
Kyung-Min Kim	04/27/20	Conference call with I. Hirsch, P. DiMatteo (KPMG US) and K. Kim and D. Shin (both KPMG South Korea) to discuss structuring and Korean tax considerations associated with contemplated dispositions with respect to a Korean Mundipharma entity	0.7	\$476	\$ 333.20
Dong-Ju Shin	04/27/20	Conference call with I. Hirsch, P. DiMatteo (KPMG US) and K. Kim and D. Shin (both KPMG South Korea) to discuss structuring and Korean tax considerations associated with contemplated dispositions with respect to a Korean Mundipharma entity	0.7	\$476	\$ 333.20
Isaac Hirsch	04/27/20	Conference call with I. Hirsch, P. DiMatteo (KPMG US) and K. Kim and D. Shin (both KPMG South Korea) to discuss structuring and Korean tax considerations associated with contemplated dispositions with respect to a Korean Mundipharma entity	0.7	\$819	\$ 573.30
Pete DiMatteo	04/27/20	Conference call with I. Hirsch, P. DiMatteo (KPMG US) and K. Kim and D. Shin (both KPMG South Korea) to discuss structuring and Korean tax considerations associated with contemplated dispositions with respect to a Korean Mundipharma entity	0.7	\$650	\$ 455.00
Ashley Armfield	04/27/20	Review of preferred equity summary, provided by M. Land - KPMG, with regards to inclusion in the Purdue cash tax summary.	0.7	\$534	\$ 373.80
Karl Tong	04/27/20	Conference call with I. Hirsch, P. DiMatteo (KPMG US) and J. Tan, K. Tong, D. Xu (KPMG China) to discuss structuring and Chinese tax considerations associated with contemplated dispositions with respect to various Chinese Mundipharma entities.	0.8	\$594	\$ 475.20
Dora Xu	04/27/20	Conference call with I. Hirsch, P. DiMatteo (KPMG US) and J. Tan, K. Tong, D. Xu (KPMG China) to discuss structuring and Chinese tax considerations associated with contemplated dispositions with respect to various Chinese Mundipharma entities.	0.8	\$315	\$ 252.00

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Joyce Tan	04/27/20	Conference call with I. Hirsch, P. DiMatteo (KPMG US) and J. Tan, K. Tong, D. Xu (KPMG China) to discuss structuring and Chinese tax considerations associated with contemplated dispositions with respect to various Chinese Mundipharma entities.	0.8	\$985	\$ 788.00
Isaac Hirsch	04/27/20	Conference call with I. Hirsch, P. DiMatteo (KPMG US) and J. Tan, K. Tong, D. Xu (KPMG China) to discuss structuring and Chinese tax considerations associated with contemplated dispositions with respect to various Chinese Mundipharma entities.	0.8	\$819	\$ 655.20
Pete DiMatteo	04/27/20	Conference call with I. Hirsch, P. DiMatteo (KPMG US) and J. Tan, K. Tong, D. Xu (KPMG China) to discuss structuring and Chinese tax considerations associated with contemplated dispositions with respect to various Chinese Mundipharma entities.	0.8	\$650	\$ 520.00
Jess Commisso	04/27/20	Summarization of Luxembourg tax consequences based on local tax expert commentary to incorporate into the cash tax model.	0.8	\$350	\$ 280.00
Douglas Holland	04/27/20	Perform Principal Washington National Tax (WNT) review of slide deck describing tax implications for dispositions of Mundipharma business	1.0	\$985	\$ 985.00
Carlotta Bertu	04/27/20	Discussion with I. Hirsch, P. DiMatteo, A. Armfield (KPMG US) and E. Graziani, L. Bellavite, and C. Bertu (KPMG Italy) regarding analysis of certain agreements and the related Italian tax treatment pursuant to properly reflecting such tax consequences in the structure deck and cash tax model.	1.1	\$214	\$ 235.40
Lorenzo Bellavite	04/27/20	Discussion with I. Hirsch, P. DiMatteo, A. Armfield (KPMG US) and E. Graziani, L. Bellavite, and C. Bertu (KPMG Italy) regarding analysis of certain agreements and the related Italian tax treatment pursuant to properly reflecting such tax consequences in the structure deck and cash tax model.	1.1	\$476	\$ 523.60
Eugenio Graziani	04/27/20	Discussion with I. Hirsch, P. DiMatteo, A. Armfield (KPMG US) and E. Graziani, L. Bellavite, and C. Bertu (KPMG Italy) regarding analysis of certain agreements and the related Italian tax treatment pursuant to properly reflecting such tax consequences in the structure deck and cash tax model.	1.1	\$476	\$ 523.60
Ashley Armfield	04/27/20	Discussion with I. Hirsch, P. DiMatteo, A. Armfield (KPMG US) and E. Graziani, L. Bellavite, and C. Bertu (KPMG Italy) regarding analysis of certain agreements and the related Italian tax treatment pursuant to properly reflecting such tax consequences in the structure deck and cash tax model.	1.1	\$534	\$ 587.40

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Isaac Hirsch	04/27/20	Discussion with I. Hirsch, P. DiMatteo, A. Armfield (KPMG US) and E. Graziani, L. Bellavite, and C. Bertu (KPMG Italy) regarding analysis of certain agreements and the related Italian tax treatment pursuant to properly reflecting such tax consequences in the structure deck and cash tax model.	1.1	\$819	\$ 900.90
Pete DiMatteo	04/27/20	Discussion with I. Hirsch, P. DiMatteo, A. Armfield (KPMG US) and E. Graziani, L. Bellavite, and C. Bertu (KPMG Italy) regarding analysis of certain agreements and the related Italian tax treatment pursuant to properly reflecting such tax consequences in the structure deck and cash tax model.	1.1	\$650	\$ 715.00
Isaac Hirsch	04/27/20	Performed Managing Director review of global structure deck with focus on updates related to consequences of certain obligations.	1.1	\$819	\$ 900.90
Claudio Mengotti	04/27/20	Performed high level tax review of proposed structuring options as provided by D. Rowles (KPMG) with regard to sale of Mundipharma entities and subsequent repatriation of funds while concurrently noting Swiss structuring comments to be included into the KPMG US structuring slides.	1.2	\$610	\$ 732.00
Jess Commisso	04/27/20	Summarization of Italian tax consequences based on local tax expert commentary to incorporate into the cash tax model.	1.6	\$350	\$ 560.00
Pete DiMatteo	04/27/20	Performed international tax manager review of Evercore valuation file (0.7) and selection of additional entities/jurisdictions (1.1) to cover in model/slide decks	1.8	\$650	\$ 1,170.00
Devon Rowles	04/27/20	1.2 Review of Korea structure deck including related cash flow in order to gain insight into Korean tax consequences resulting from KPMG US management's call with Korean tax specialists; 1.1 Review of China structure deck including related cash flow in order to gain insight into Chinese tax consequences resulting from KPMG US management's call with Chinese tax specialists	2.3	\$350	\$ 805.00
Ashley Armfield	04/27/20	Update of Evercore valuation summary (provided by M. Land and M. DiMatteo - both KPMG) for purposes of the cash tax model.	2.6	\$534	\$ 1,388.40
Ashley Armfield	04/27/20	Update the Purdue cash tax model based on results of discussions with M. Hoffenberg and T. Stone (both KPMG WNT) relating to overall cash flow and tax assumptions.	2.8	\$534	\$ 1,495.20
Isaac Hirsch	04/27/20	Performed Managing Director review of latest version of global cash tax model with regards to updates related to US trust tax consequences for comments from KPMG WNT.	2.9	\$819	\$ 2,375.10

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Devon Rowles	04/27/20	3.1 Updates to the valuation allocation for various Mundipharma entities based on Manager review comments received from P. DiMatteo - KPMG) pursuant to including the valuation in the cash tax model	3.1	\$350	\$ 1,085.00
Pete DiMatteo	04/27/20	Performed international tax manager review and concurrently revised slide deck depicting various contemplated payments to be made by a UK entity in connection with multiple arrangements.	3.1	\$650	\$ 2,015.00
Casey Nunez	04/27/20	3.0 Preparation of visual cash flow/structure summary in cash tax model to aid review by KPMG partners and client	3.0	\$744	\$ 2,232.00
Isaac Hirsch	04/27/20	Revised the global cash tax model for cash tax consequences of certain obligation payments.	3.4	\$819	\$ 2,784.60
Casey Nunez	04/27/20	1.4 Performed M&A Senior Manager review of Canada disposition calculation; 2.2 Performed M&A senior manager review of trust cash flow summary in the cash tax model.	3.6	\$744	\$ 2,678.40
Becky Holtje	04/27/20	Began to perform technical research into whether certain payments are ordinary and necessary expenses to facilitate U.S. cash tax modeling	3.9	\$744	\$ 2,901.60
Michael Land	04/27/20	Updates to Evercore valuation summary for purposes of capturing the full chain of entities as well as value under analysis	3.9	\$534	\$ 2,082.60
Ashley Armfield	04/27/20	Updating cash tax model to reflect different scenarios relating to certain theories relating to potential liabilities.	3.9	\$534	\$ 2,082.60
Sara Gonzalez Perez	04/28/20	Performed Associate level review (from a Luxembourg tax perspective) of the second additional slide deck provided by the U.S. team regarding the Mundipharma Disposition Analysis	0.2	\$380	\$ 76.00
Sara Gonzalez Perez	04/28/20	Performed Associate level review of the first additional slide deck provided by the U.S. team regarding the Mundipharma Disposition Analysis (i.e. the Additional Jurisdictions slide deck)	0.3	\$380	\$ 114.00
Yaniv Hertz	04/28/20	Performed Partner review of financial statements for an Israeli entity (0.2) and potential disposition re same (0.1) in preparation for call (on same day) with KPMG US.	0.3	\$555	\$ 166.50
Sara Gonzalez Perez	04/28/20	Meeting with R. Lijzenga, S. Perez and A. Merelles (all KPMG Luxembourg) to discuss the additional dispositions for certain agreements slide deck and high-level tax comments to be provided.	0.4	\$380	\$ 152.00
Robin Lijzenga	04/28/20	Meeting with R. Lijzenga, S. Perez and A. Merelles (all KPMG Luxembourg) to discuss the additional dispositions for certain agreements slide deck and high-level tax comments to be provided.	0.4	\$730	\$ 292.00

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Alejandro Merelles Rodriguez	04/28/20	Meeting with R. Lijzenga, S. Perez and A. Merelles (all KPMG Luxembourg) to discuss the additional dispositions for certain agreements slide deck and high-level tax comments to be provided.	0.4	\$640	\$ 256.00
Tracy Stone	04/28/20	0.5 Performed analysis regarding impact of COVID legislation on prior tax years of trusts and individual beneficiaries of same.	0.5	\$906	\$ 453.00
Denis Larkin	04/28/20	Conference call with I. Hirsch, P. DiMatteo (KPMG US) and J. Davis, D. Larkin, H. Lewis (KPMG Australia) to discuss structuring and Australian tax considerations associated with contemplated disposition sales with respect to an Australian Mundipharma entity	0.5	\$566	\$ 283.00
Justin Davis	04/28/20	Conference call with I. Hirsch, P. DiMatteo (KPMG US) and J. Davis, D. Larkin, H. Lewis (KPMG Australia) to discuss structuring and Australian tax considerations associated with contemplated disposition sales with respect to an Australian Mundipharma entity	0.5	\$655	\$ 327.50
Hanah Lewis	04/28/20	Conference call with I. Hirsch, P. DiMatteo (KPMG US) and J. Davis, D. Larkin, H. Lewis (KPMG Australia) to discuss structuring and Australian tax considerations associated with contemplated disposition sales with respect to an Australian Mundipharma entity	0.5	\$239	\$ 119.50
Isaac Hirsch	04/28/20	Conference call with I. Hirsch, P. DiMatteo (KPMG US) and J. Davis, D. Larkin, H. Lewis (KPMG Australia) to discuss structuring and Australian tax considerations associated with contemplated disposition sales with respect to an Australian Mundipharma entity	0.5	\$819	\$ 409.50
Pete DiMatteo	04/28/20	Conference call with I. Hirsch, P. DiMatteo (KPMG US) and J. Davis, D. Larkin, H. Lewis (KPMG Australia) to discuss structuring and Australian tax considerations associated with contemplated disposition sales with respect to an Australian Mundipharma entity	0.5	\$650	\$ 325.00
Alejandro Merelles Rodriguez	04/28/20	Review of the European Parent Subsidiary Directive in order to determine if European entities may qualify for the Luxembourg participation regime	0.5	\$640	\$ 320.00
Lukas van der Veen	04/28/20	Manager level review (from a Dutch tax perspective) of slide deck prepared by KPMG US on the disposal of a Dutch entity	0.6	\$565	\$ 339.00
Robin Lijzenga	04/28/20	Meeting with A. Merelles, R. Lijzenga and S. Gonzalez (all KPMG Luxembourg) to discuss the additional dispositions depicted in the Additional Jurisdictions slide deck and high-level tax comments to be provided.	0.6	\$730	\$ 438.00

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount	
Alejandro Merelles Rodriguez	04/28/20	Meeting with A. Merelles, R. Lijzenga and S. Gonzalez (all KPMG Luxembourg) to discuss the additional dispositions depicted in the Additional Jurisdictions slide deck and high-level tax comments to be provided.	0.6	\$640	\$ 384.	00
Sara Gonzalez Perez	04/28/20	Meeting with A. Merelles, R. Lijzenga and S. Gonzalez (all KPMG Luxembourg) to discuss the additional dispositions depicted in the Additional Jurisdictions slide deck and high-level tax comments to be provided.	0.6	\$380	\$ 228.	00
Sara Gonzalez Perez	04/28/20	Performed analysis of Australian tax system (new jurisdiction added to the Additional Jurisdictions slide deck as regards the Mundipharma Disposition Analysis) in order to determine potential tax consequences	0.6	\$380	\$ 228.	00
Alejandro Merelles Rodriguez	04/28/20	Review of the Double Tax Treaty Between South Africa and Luxembourg in order to confirm the potential application of the Luxembourg participation exemption regime to a potential disposition	0.6	\$640	\$ 384.	00
Arik Eytan	04/28/20	Call with I. Hirsch, P. DiMatteo (KPMG US) and A. Eytan and Y. Hertz (KPMG Israel) to discuss statutory and withholding tax rates applicable to the disposition of the Israeli Mundipharma entity and the related distribution of proceeds pursuant to including the appropriate rates in the structure deck and cash tax model.	0.7	\$555	\$ 388.	50
Yaniv Hertz	04/28/20	Call with I. Hirsch, P. DiMatteo (KPMG US) and A. Eytan and Y. Hertz (KPMG Israel) to discuss statutory and withholding tax rates applicable to the disposition of the Israeli Mundipharma entity and the related distribution of proceeds pursuant to including the appropriate rates in the structure deck and cash tax model.	0.7	\$555	\$ 388.	50
Isaac Hirsch	04/28/20	Call with I. Hirsch, P. DiMatteo (KPMG US) and A. Eytan and Y. Hertz (KPMG Israel) to discuss statutory and withholding tax rates applicable to the disposition of the Israeli Mundipharma entity and the related distribution of proceeds pursuant to including the appropriate rates in the structure deck and cash tax model.	0.7	\$819	\$ 573.	30
Pete DiMatteo	04/28/20	Call with I. Hirsch, P. DiMatteo (KPMG US) and A. Eytan and Y. Hertz (KPMG Israel) to discuss statutory and withholding tax rates applicable to the disposition of the Israeli Mundipharma entity and the related distribution of proceeds pursuant to including the appropriate rates in the structure deck and cash tax model.	0.7	\$650	\$ 455.	00
Rob Keller	04/28/20	Call with T. Stone and R. Keller (both KPMG WNT) to discuss potential impact of COVID legislation on the company	0.7	\$893	\$ 625.	10

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Tracy Stone	04/28/20	Call with T. Stone and R. Keller (both KPMG WNT) to discuss potential impact of COVID legislation on the company	0.7	\$906	\$ 634.20
Lukas van der Veen	04/28/20	Manager level review (from a Dutch tax perspective) of slide deck prepared by KPMG US on the disposal of a Dutch entity	0.7	\$565	\$ 395.50
Casey Nunez	04/28/20	Call with R. Keller (KPMG WNT pass-through specialist), T. Stone (KPMG WNT trust specialist) and I. Hirsch, C. Nunez, M. Land (all KPMG) internal call with to discuss the potential impact of the CARES Act to the tax filing profile of certain trusts and individuals	0.8	\$744	\$ 595.20
Isaac Hirsch	04/28/20	Call with R. Keller (KPMG WNT pass-through specialist), T. Stone (KPMG WNT trust specialist) and I. Hirsch, C. Nunez, M. Land (all KPMG) internal call with to discuss the potential impact of the CARES Act to the tax filing profile of certain trusts and individuals	0.8	\$819	\$ 655.20
Michael Land	04/28/20	Call with R. Keller (KPMG WNT pass-through specialist), T. Stone (KPMG WNT trust specialist) and I. Hirsch, C. Nunez, M. Land (all KPMG) internal call with to discuss the potential impact of the CARES Act to the tax filing profile of certain trusts and individuals	0.8	\$534	\$ 427.20
Rob Keller	04/28/20	Call with R. Keller (KPMG WNT pass-through specialist), T. Stone (KPMG WNT trust specialist) and I. Hirsch, C. Nunez, M. Land (all KPMG) internal call with to discuss the potential impact of the CARES Act to the tax filing profile of certain trusts and individuals	0.8	\$893	\$ 714.40
Tracy Stone	04/28/20	Call with R. Keller (KPMG WNT pass-through specialist), T. Stone (KPMG WNT trust specialist) and I. Hirsch, C. Nunez, M. Land (all KPMG) internal call with to discuss the potential impact of the CARES Act to the tax filing profile of certain trusts and individuals	0.8	\$906	\$ 724.80
Paul Harden	04/28/20	Discussion with I. Hirsch, C. Nunez, A. Armfield, J. Commisso (KPMGUS) and P. Harden, G. Little and M. Latham (KPMG UK) regarding a potential deduction of US taxes for UK taxation purposes at the trust level, and the appropriate tax treatment of certain agreements between the associated UK Mundipharma entity and various jurisdictions.	0.8	\$985	\$ 788.00
Gavin Little	04/28/20	Discussion with I. Hirsch, C. Nunez, A. Armfield, J. Commisso (KPMGUS) and P. Harden, G. Little and M. Latham (KPMG UK) regarding a potential deduction of US taxes for UK taxation purposes at the trust level, and the appropriate tax treatment of certain agreements between the associated UK Mundipharma entity and various jurisdictions.	0.8	\$985	\$ 788.00

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Madeleine Latham	04/28/20	Discussion with I. Hirsch, C. Nunez, A. Armfield, J. Commisso (KPMGUS) and P. Harden, G. Little and M. Latham (KPMG UK) regarding a potential deduction of US taxes for UK taxation purposes at the trust level, and the appropriate tax treatment of certain agreements between the associated UK Mundipharma entity and various jurisdictions.	0.8	\$343	\$ 274.40
Casey Nunez	04/28/20	Discussion with I. Hirsch, C. Nunez, A. Armfield, J. Commisso (KPMGUS) and P. Harden, G. Little and M. Latham (KPMG UK) regarding a potential deduction of US taxes for UK taxation purposes at the trust level, and the appropriate tax treatment of certain agreements between the associated UK Mundipharma entity and various jurisdictions.	0.8	\$744	\$ 595.20
Ashley Armfield	04/28/20	Discussion with I. Hirsch, C. Nunez, A. Armfield, J. Commisso (KPMGUS) and P. Harden, G. Little and M. Latham (KPMG UK) regarding a potential deduction of US taxes for UK taxation purposes at the trust level, and the appropriate tax treatment of certain agreements between the associated UK Mundipharma entity and various jurisdictions.	0.8	\$534	\$ 427.20
Isaac Hirsch	04/28/20	Discussion with I. Hirsch, C. Nunez, A. Armfield, J. Commisso (KPMGUS) and P. Harden, G. Little and M. Latham (KPMG UK) regarding a potential deduction of US taxes for UK taxation purposes at the trust level, and the appropriate tax treatment of certain agreements between the associated UK Mundipharma entity and various jurisdictions.	0.8	\$819	\$ 655.20
Jess Commisso	04/28/20	Discussion with I. Hirsch, C. Nunez, A. Armfield, J. Commisso (KPMGUS) and P. Harden, G. Little and M. Latham (KPMG UK) regarding a potential deduction of US taxes for UK taxation purposes at the trust level, and the appropriate tax treatment of certain agreements between the associated UK Mundipharma entity and various jurisdictions.	0.8	\$350	\$ 280.00
Claudio Mengotti	04/28/20	Continued (from 4/27) to perform high level tax review of proposed structuring options as provided by D. Rowles (KPMG) with regard to sale of Mundipharma entities and subsequent repatriation of funds while concurrently noting Swiss structuring comments to be included into the KPMG US structuring slides.	0.9	\$610	\$ 549.00
Aroen Rambhadjan	04/28/20	Partner level review (from a Dutch tax perspective) of slide deck prepared by KPMG US on the disposal of a Dutch entity (Dutch entity 1)	0.9	\$884	\$ 795.60
Aroen Rambhadjan	04/28/20	Partner level review (from a Dutch tax perspective) of slide deck prepared by KPMG US on the disposal of a Dutch entity (Dutch entity 2)	0.9	\$884	\$ 795.60

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Sara Gonzalez Perez	04/28/20	Perform analysis of the application of the General Anti-Abuse Rule (GAAR) to the income received by some LuxCos if derived from low tax jurisdictions in order to be included in the Additional Jurisdiction slide deck of the Mundipharma Disposition Analysis	0.9	\$380	\$ 342.00
Becky Holtje	04/28/20	Continue, same day, to perform technical research into whether certain payments are ordinary and necessary expenses to facilitate U.S. cash tax modeling	1.2	\$744	\$ 892.80
Devon Rowles	04/28/20	1.3 Updates to the cash tax model with respect to preferred equity outstanding for various Mundipharma entities	1.3	\$350	\$ 455.00
Ashley Armfield	04/28/20	(1.6) Call with D. Holland, I. Hirsch, C. Nunez, and A. Armfield (all KPMG) to discuss review of cash tax model regarding potential foreign taxes and United Kingdom tax calculation.	1.6	\$534	\$ 854.40
Isaac Hirsch	04/28/20	(1.6) Call with D. Holland, I. Hirsch, C. Nunez, and A. Armfield (all KPMG) to discuss review of cash tax model regarding potential foreign taxes and United Kingdom tax calculation.	1.6	\$819	\$ 1,310.40
Casey Nunez	04/28/20	(1.6) Call with D. Holland, I. Hirsch, C. Nunez, and A. Armfield (all KPMG) to discuss review of cash tax model regarding potential foreign taxes and United Kingdom tax calculation.	1.6	\$744	\$ 1,190.40
Douglas Holland	04/28/20	(1.6) Call with D. Holland, I. Hirsch, C. Nunez, and A. Armfield (all KPMG) to discuss review of cash tax model regarding potential foreign taxes and United Kingdom tax calculation.	1.6	\$985	\$ 1,576.00
Dora Xu	04/28/20	Perform initial senior associate level review of transaction steps presentation slides provided by P. DiMatteo (KPMG US), simultaneously drafting review comments related to same.	1.6	\$315	\$ 504.00
Michael Land	04/28/20	0.6 Review of structure deck that contemplates the disposition of an Australian entity; 1.1 review of notes / assumptions to preferred interests for purposes of implementation into the Purdue cash tax model	1.7	\$534	\$ 907.80
Casey Nunez	04/28/20	2.1 Performed M&A Senior Manager review of US corporate income tax calculations	2.1	\$744	\$ 1,562.40
Ashley Armfield	04/28/20	0.8 Updated Purdue cash tax model for outstanding preferred equity relating to the mundipharma entities; 1.2 Reviewed structuring deck with regards to including concepts into cash tax model. 0.2 Review of Israel tax specialist call notes pursuant to incorporation into the Purdue cash tax model.	2.2	\$534	\$ 1,174.80
Rob Keller	04/28/20	Performed analysis CARES Act to facilitate response to Province regarding any potential impact	2.2	\$893	\$ 1,964.60

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Pete DiMatteo	04/28/20	Perform international tax manager review and concurrently revised slide deck depicting various contemplated transactions, including anticipated U.S. tax considerations regarding same.	2.3	\$650	\$ 1,495.00
Pete DiMatteo	04/28/20	2.4 Performed international tax manager review and concurrently revised slide deck depicting various transactions related to Dutch entities.	2.4	\$650	\$ 1,560.00
Michael Land	04/28/20	(1.3) Draft email related to CARES act analysis in preparation for senior manager review (1.1) Senior Associate review of updates to preferred share summary analysis for purposes of input into the cash tax model	2.4	\$534	\$ 1,281.60
Casey Nunez	04/28/20	2.4 Performed M&A Senior Manager Review of Norton Rose versus KPMG tax calculation comparison summary	2.4	\$744	\$ 1,785.60
Alejandro Merelles Rodriguez	04/28/20	Drafted high-level Luxembourg direct tax comments related to certain agreements slide deck regarding the Mundipharma Disposition Analysis	3.1	\$640	\$ 1,984.00
Jess Commisso	04/28/20	0.8 Summarization of potential Israeli tax consequences based on local tax expert commentary to incorporate into the cash tax model. 2.6 Creation of comparison chart between our cash tax model values and Norton Rose computation values to highlight the tax differences.	3.4	\$350	\$ 1,190.00
Devon Rowles	04/28/20	0.9 Review of Australia structure deck along with related cash flow in order to gain insight into Australian tax consequences resulting from KPMG US management's call with Australian tax specialists; 2.6 Updates to the Purdue cash tax model based on senior associate review comments received, specifically related to the potential disposition of Mundipharma United Kingdom entity	3.5	\$350	\$ 1,225.00
Jess Commisso	04/28/20	1.8 Incorporation of certain tax rates into the cash tax model pursuant to certain agreements; 1.8 Updated model flowchart (how the cash tax model is set up for purposes of simpler explanation / understanding) to match model updates.	3.6	\$350	\$ 1,260.00
Jess Commisso	04/28/20	3.6 Review of Evercore valuation to determine if there are any other Mundipharma entities that could potentially be disposition entities within our cash tax model.	3.6	\$350	\$ 1,260.00
Isaac Hirsch	04/28/20	(1.7) Perform Managing director review of updates to cash tax model to reflect incorporation of certain agreements provided by Norton Rose; (1.1) analyze potential impact of CARES act for purposes of cash tax modeling; (0.9) draft email to H. Steinberg (KPMG) regarding analysis of same.	3.7	\$819	\$ 3,030.30
Ashley Armfield	04/28/20	3.9 Revised the Purdue cash tax model to reflect updates related to potential deductions as of $4/28/2020$.	3.9	\$534	\$ 2,082.60

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Ashley Armfield	04/28/20	3.9 Updating model sourcing for US tax calculation in the cash tax model based on review comments received to date.	3.9	\$534	\$ 2,082.60
Becky Holtje	04/28/20	Continue, as of 4/27, to perform technical research into whether certain payments are ordinary and necessary expenses to facilitate U.S. cash tax modeling	3.9	\$744	\$ 2,901.60
Sara Gonzalez Perez	04/28/20	Drafted high-level Luxembourg direct tax comments on the additional dispositions depicted in the Additional Jurisdictions slide deck regarding the Mundipharma Disposition Analysis	3.9	\$380	\$ 1,482.00
Alejandro Merelles Rodriguez	04/29/20	Review of the application of the General Anti-Abuse Rule (GAAR) to the income received by some LuxCos if derived from low tax jurisdictions	0.3	\$640	\$ 192.00
Bela Unell	04/29/20	0.4 Performed Senior Manager Washington National tax review of review Purdue cash tax model as of 4/29/2020 - in preparation for calls (on same day).	0.4	\$744	\$ 297.60
Devon Rowles	04/29/20	Continue, from earlier in the day, to update the Purdue cash tax model based on review comments received from A. Armfield (KPMG) on 4/29/2020.	0.4	\$350	\$ 140.00
Douglas Holland	04/29/20	Performed Washington National tax analysis in order to resolve treatment of certain taxes as input to cash tax model.	0.5	\$985	\$ 492.50
Carlotta Bertu	04/29/20	Continue (same day) to update structure deck "Purdue - Italy slides" (received on April 27th) following discussion with the KPMG US team while concurrently drafting Italian tax comments where requested.	0.8	\$214	\$ 171.20
Claudio Mengotti	04/29/20	Continue (from previous day) to perform high level tax review of proposed structuring options as provided by D. Rowles (KPMG) with regard to potential sale of Mundipharma entities	0.9	\$610	\$ 549.00
Emilien Lebas	04/29/20	Final Partner review of the draft high-level Luxembourg direct tax comments re certain agreements	0.9	\$985	\$ 886.50
Tracy Stone	04/29/20	0.5 Review and concurrently revise email regarding CARES Act impact; 0.5 consider tax consequences of potential distributions to a US beneficiary and concurrently drafted email to I. Hirsch (KPMG) regarding same.	1.0	\$906	\$ 906.00
Karl Tong	04/29/20	Performed Manager level review of transaction steps presentation slides provided by P. DiMatteo (KPMG US) along with review comments (related to same) provided by D. Xu (KPMG China)	1.0	\$594	\$ 594.00
Isaac Hirsch	04/29/20	(1.1) Preparation of structure for UK disposition structure for incorporation into Purdue cash tax model	1.1	\$819	\$ 900.90

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Ashley Armfield	04/29/20	Discussion with M. Hoffenberg (KPMG WNT), D. Holland (KPMG WNT), B. Unell (KPMG WNT), S. Xu (KPMG WNT), I. Hirsch, C. Nunez, P. DiMatteo, A. Armfield, and J. Commisso (all KPMG) to discuss the Purdue cash tax model with focus on inclusion of potential tax consequences arising from various potential disposition scenarios presented.	1.1	\$534	\$ 587.40
Isaac Hirsch	04/29/20	Discussion with M. Hoffenberg (KPMG WNT), D. Holland (KPMG WNT), B. Unell (KPMG WNT), S. Xu (KPMG WNT), I. Hirsch, C. Nunez, P. DiMatteo, A. Armfield, and J. Commisso (all KPMG) to discuss the Purdue cash tax model with focus on inclusion of potential tax consequences arising from various potential disposition scenarios presented.	1.1	\$819	\$ 900.90
Bela Unell	04/29/20	Discussion with M. Hoffenberg (KPMG WNT), D. Holland (KPMG WNT), B. Unell (KPMG WNT), S. Xu (KPMG WNT), I. Hirsch, C. Nunez, P. DiMatteo, A. Armfield, and J. Commisso (all KPMG) to discuss the Purdue cash tax model with focus on inclusion of potential tax consequences arising from various potential disposition scenarios presented.	1.1	\$744	\$ 818.40
Casey Nunez	04/29/20	Discussion with M. Hoffenberg (KPMG WNT), D. Holland (KPMG WNT), B. Unell (KPMG WNT), S. Xu (KPMG WNT), I. Hirsch, C. Nunez, P. DiMatteo, A. Armfield, and J. Commisso (all KPMG) to discuss the Purdue cash tax model with focus on inclusion of potential tax consequences arising from various potential disposition scenarios presented.	1.1	\$744	\$ 818.40
Jess Commisso	04/29/20	Discussion with M. Hoffenberg (KPMG WNT), D. Holland (KPMG WNT), B. Unell (KPMG WNT), S. Xu (KPMG WNT), I. Hirsch, C. Nunez, P. DiMatteo, A. Armfield, and J. Commisso (all KPMG) to discuss the Purdue cash tax model with focus on inclusion of potential tax consequences arising from various potential disposition scenarios presented.	1.1	\$350	\$ 385.00
Serena Xu	04/29/20	Discussion with M. Hoffenberg (KPMG WNT), D. Holland (KPMG WNT), B. Unell (KPMG WNT), S. Xu (KPMG WNT), I. Hirsch, C. Nunez, P. DiMatteo, A. Armfield, and J. Commisso (all KPMG) to discuss the Purdue cash tax model with focus on inclusion of potential tax consequences arising from various potential disposition scenarios presented.	1.1	\$744	\$ 818.40
Douglas Holland	04/29/20	Discussion with M. Hoffenberg (KPMG WNT), D. Holland (KPMG WNT), B. Unell (KPMG WNT), S. Xu (KPMG WNT), I. Hirsch, C. Nunez, P. DiMatteo, A. Armfield, and J. Commisso (all KPMG) to discuss the Purdue cash tax model with focus on inclusion of potential tax consequences arising from various potential disposition scenarios presented.	1.1	\$985	\$ 1,083.50

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Mark Hoffenberg	04/29/20	Discussion with M. Hoffenberg (KPMG WNT), D. Holland (KPMG WNT), B. Unell (KPMG WNT), S. Xu (KPMG WNT), I. Hirsch, C. Nunez, P. DiMatteo, A. Armfield, and J. Commisso (all KPMG) to discuss the Purdue cash tax model with focus on inclusion of potential tax consequences arising from various potential disposition scenarios presented.	1.1	\$980	\$ 1,078.00
Pete DiMatteo	04/29/20	Discussion with M. Hoffenberg (KPMG WNT), D. Holland (KPMG WNT), B. Unell (KPMG WNT), S. Xu (KPMG WNT), I. Hirsch, C. Nunez, P. DiMatteo, A. Armfield, and J. Commisso (all KPMG) to discuss the Purdue cash tax model with focus on inclusion of potential tax consequences arising from various potential disposition scenarios presented.	1.1	\$650	\$ 715.00
Pete DiMatteo	04/29/20	Performed international tax manager review and concurrently revised slide deck depicting various contemplated transactions, including anticipated U.S. tax considerations regarding same.	1.2	\$650	\$ 780.00
Paul Harden	04/29/20	Review and concurrently prepare analysis regarding the information provided by KPMG US regarding the UK tax implications of certain agreements in place between Mundipharma entities.	1.2	\$985	\$ 1,182.00
Jess Commisso	04/29/20	1.3 Continued (same day) to review formulas and cash allocations within cash tax model to ensure accuracy.	1.3	\$350	\$ 455.00
Alejandro Merelles Rodriguez	04/29/20	Review of the final version of the additional dispositions depicted in the structure charts for certain agreements slide deck, that includes changes made by the Partner E. Lebas (KPMG) while concurrently adapting with regards to consistency in corresponding version.	1.3	\$640	\$ 832.00
Emilien Lebas	04/29/20	Partner review of the draft high-level Luxembourg direct tax comments on the "Additional Jurisdictions" slide deck	1.4	\$985	\$ 1,379.00
Robin Lijzenga	04/29/20	Performed Manager review of the draft high-level Luxembourg direct tax comments on Structure charts for certain agreement slide deck	1.5	\$730	\$ 1,095.00
Pete DiMatteo	04/29/20	1.8 Perform international tax manager review and concurrently revised slide deck depicting various contemplated certain transactions, including anticipated U.S. tax considerations regarding same.	1.8	\$650	\$ 1,170.00
Becky Holtje	04/29/20	Continued, same day, to perform technical research into whether certain payments are ordinary and necessary expenses to facilitate U.S. cash tax modeling	2.1	\$744	\$ 1,562.40
Robin Lijzenga	04/29/20	Performed Manager review of the draft high-level Luxembourg direct tax comments on the "Additional Jurisdictions" slide deck	2.1	\$730	\$ 1,533.00

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Pete DiMatteo	04/29/20	2.2 Perform international tax manager review and concurrently revised slide deck depicting various contemplated certain transactions, including anticipated U.S. tax considerations regarding same.	2.2	\$650	\$ 1,430.00
Casey Nunez	04/29/20	2.6 Performed M&A Senior Manager review of most recent version of the overall cash tax model flow to ensure accuracy.	2.6	\$744	\$ 1,934.40
Lukas van der Veen	04/29/20	Draft Dutch tax comments related to review of deck on the disposal of a Dutch entity prepared by KPMG US.	2.6	\$565	\$ 1,469.00
Ashley Armfield	04/29/20	2.9 Updating cash tax model based on director and senior manager review comments received as of 4/29/2020 specifically relating to US tax calculation for individuals, trusts and corporations.	2.9	\$534	\$ 1,548.60
Isaac Hirsch	04/29/20	(3.1) Performed Managing Director review of cash tax model with focus on confirming updates related to my comments to UK disposition structure	3.1	\$819	\$ 2,538.90
Carlotta Bertu	04/29/20	Updated structure deck, received on Apr, 27th following discussion with the KPMG US team while concurrently drafting Italian tax comments where requested.	3.1	\$214	\$ 663.40
Alejandro Merelles Rodriguez	04/29/20	Senior Associate review of the high-level Luxembourg direct tax comments on the additional dispositions depicted in one of the new slide decks regarding the Mundipharma Disposition Analysis (i.e. Additional Jurisdictions).	3.2	\$640	\$ 2,048.00
Hanah Lewis	04/29/20	Drafting Australian tax comments for inclusion in document titled Mundipharma Disposition Analysis detailing the Australian tax consequences arising from potential dispositions	3.8	\$239	\$ 908.20
Jess Commisso	04/29/20	3.9 Review of formulas and cash allocations within cash tax model to ensure accuracy.	3.9	\$350	\$ 1,365.00
Ashley Armfield	04/29/20	3.9 Updated the Purdue cash tax model for disposition of United Kingdom entity that has outstanding agreements with more than ten (10) other entities in the Mundipharma structure.	3.9	\$534	\$ 2,082.60
Ashley Armfield	04/29/20	3.9 Updating the Purdue cash tax model for disposition of United Kingdom entity (with regards to another disposition scenario) that has outstanding funding agreements with more than ten (10) other entities in the Mundipharma structure.	3.9	\$534	\$ 2,082.60
Devon Rowles	04/29/20	Began to update the Purdue cash tax model based on review comments received from A. Armfield (KPMG) on 4/29/2020.	3.9	\$350	\$ 1,365.00
Becky Holtje	04/29/20	Continue, from previous day, to perform technical research into whether certain payments are ordinary and necessary expenses to facilitate U.S. cash tax modeling	3.9	\$744	\$ 2,901.60

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Carlotta Bertu	04/29/20	Updated structure deck "Purdue - Italy slides" (received on April 27th) following discussion with the KPMG US team while concurrently drafting Italian tax comments where requested.	3.9	\$214	\$ 834.60
Devon Rowles	04/30/20	Updated the Purdue cash tax model with regards to received comments received from A. Armfield (KPMG) on 4/30/2020.	0.4	\$350	\$ 140.00
Sara Gonzalez Perez	04/30/20	Final review of Structure chart for certain agreements slide deck after partner's review (e.g. updates, appendices inclusion, etc.) prior to sending to KPMG U.S. team	0.5	\$380	\$ 190.00
Robin Lijzenga	04/30/20	Inclusion of final comments as regards the application of the General Anti-Abuse Rule (GAAR) to the income receive by some LuxCos if derived from low tax jurisdictions	0.5	\$730	\$ 365.00
Curt Wilson	04/30/20	Telephone call with C. Wilson, T. Stone and R. Keller (all KPMG) to discuss impact of CARES Act on potential dispositions	0.5	\$744	\$ 372.00
Rob Keller	04/30/20	Telephone call with C. Wilson, T. Stone and R. Keller (all KPMG) to discuss impact of CARES Act on potential dispositions	0.5	\$893	\$ 446.50
Tracy Stone	04/30/20	Telephone call with C. Wilson, T. Stone and R. Keller (all KPMG) to discuss impact of CARES Act on potential dispositions	0.5	\$906	\$ 453.00
Mark Hoffenberg	04/30/20	(0.4) Performed analysis related to certain potential deductions and (0.2) email communication with KPMG Project team regarding results related to same.	0.6	\$980	\$ 588.00
Sara Gonzalez Perez	04/30/20	Finalized Jurisdictions slide deck following Partner's review (appendices inclusion, etc.) prior to providing to KPMG U.S. team	0.6	\$380	\$ 228.00
Michael Land	04/30/20	Review of term sheet with focus on potential exclusions to disposition entities.	0.7	\$534	\$ 373.80
Carlotta Bertu	04/30/20	Finalize updates to structure deck ""Purdue - Italy slides" (received on April 27th) following discussion with the KPMG US team including drafting of Italian tax comments where requested.	0.8	\$214	\$ 171.20
Pete DiMatteo	04/30/20	Performed international tax manager review of slide deck depicting various transactions, including contemplated transactions involving various trusts.	0.8	\$650	\$ 520.00
Isaac Hirsch	04/30/20	Discussion with M. Hoffenberg (WNT), D. Holland (WNT), B. Unell (WNT), S. Xu (WNT), I. Hirsch, C. Nunez, P. DiMatteo, A. Armfield, and J. Commisso (all KPMG) regarding the appropriate incorporation of certain UK agreements into the cash tax model and overall deliverable to the client.	0.9	\$819	\$ 737.10

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	A	Amount
Ashley Armfield	04/30/20	Discussion with M. Hoffenberg (WNT), D. Holland (WNT), B. Unell (WNT), S. Xu (WNT), I. Hirsch, C. Nunez, P. DiMatteo, A. Armfield, and J. Commisso (all KPMG) regarding the appropriate incorporation of certain UK agreements into the cash tax model and overall deliverable to the client.	0.9	\$534	\$	480.60
Bela Unell	04/30/20	Discussion with M. Hoffenberg (WNT), D. Holland (WNT), B. Unell (WNT), S. Xu (WNT), I. Hirsch, C. Nunez, P. DiMatteo, A. Armfield, and J. Commisso (all KPMG) regarding the appropriate incorporation of certain UK agreements into the cash tax model and overall deliverable to the client.	0.9	\$744	\$	669.60
Serena Xu	04/30/20	Discussion with M. Hoffenberg (WNT), D. Holland (WNT), B. Unell (WNT), S. Xu (WNT), I. Hirsch, C. Nunez, P. DiMatteo, A. Armfield, and J. Commisso (all KPMG) regarding the appropriate incorporation of certain UK agreements into the cash tax model and overall deliverable to the client.	0.9	\$744	\$	669.60
Casey Nunez	04/30/20	Discussion with M. Hoffenberg (WNT), D. Holland (WNT), B. Unell (WNT), S. Xu (WNT), I. Hirsch, C. Nunez, P. DiMatteo, A. Armfield, and J. Commisso (all KPMG) regarding the appropriate incorporation of certain UK agreements into the cash tax model and overall deliverable to the client.	0.9	\$744	\$	669.60
Jess Commisso	04/30/20	Discussion with M. Hoffenberg (WNT), D. Holland (WNT), B. Unell (WNT), S. Xu (WNT), I. Hirsch, C. Nunez, P. DiMatteo, A. Armfield, and J. Commisso (all KPMG) regarding the appropriate incorporation of certain UK agreements into the cash tax model and overall deliverable to the client.	0.9	\$350	\$	315.00
Douglas Holland	04/30/20	Discussion with M. Hoffenberg (WNT), D. Holland (WNT), B. Unell (WNT), S. Xu (WNT), I. Hirsch, C. Nunez, P. DiMatteo, A. Armfield, and J. Commisso (all KPMG) regarding the appropriate incorporation of certain UK agreements into the cash tax model and overall deliverable to the client.	0.9	\$985	\$	886.50
Mark Hoffenberg	04/30/20	Discussion with M. Hoffenberg (WNT), D. Holland (WNT), B. Unell (WNT), S. Xu (WNT), I. Hirsch, C. Nunez, P. DiMatteo, A. Armfield, and J. Commisso (all KPMG) regarding the appropriate incorporation of certain UK agreements into the cash tax model and overall deliverable to the client.	0.9	\$980	\$	882.00
Pete DiMatteo	04/30/20	Discussion with M. Hoffenberg (WNT), D. Holland (WNT), B. Unell (WNT), S. Xu (WNT), I. Hirsch, C. Nunez, P. DiMatteo, A. Armfield, and J. Commisso (all KPMG) regarding the appropriate incorporation of certain UK agreements into the cash tax model and overall deliverable to the client.	0.9	\$650	\$	585.00

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Pete DiMatteo	04/30/20	Performed international tax manager review and concurrently revised slide deck depicting various contemplated transactions relating to Chinese entities, including anticipated Chinese tax considerations regarding same.	0.9	\$650	\$ 585.00
Eugenio Graziani	04/30/20	Performed Partner review of the structure deck (from an Italian tax perspective), received on Apr, 27th following discussion with KPMG US team, while concurrently drafting tax comments where requested.	1.1	\$476	\$ 523.60
Jess Commisso	04/30/20	1.2 Compiled ownership and applicable tax rates for our new Mundipharma disposition entities pursuant to incorporation into the cash tax model	1.2	\$350	\$ 420.00
Denis Larkin	04/30/20	Review of draft Australian tax comments included within document titled Mundipharma Disposition Analysis - drafted by H. Lewis (KPMG Australia) and performing amendments to comments as needed.	1.3	\$566	\$ 735.80
Ashley Armfield	04/30/20	Discussion with A. Armfield, D. Rowles and J. Commisso (KPMG) regarding updates to be made to cash tax model to include additional entities (10 additional entities).	1.4	\$534	\$ 747.60
Devon Rowles	04/30/20	Discussion with A. Armfield, D. Rowles and J. Commisso (KPMG) regarding updates to be made to cash tax model to include additional entities (10 additional entities).	1.4	\$350	\$ 490.00
Jess Commisso	04/30/20	Discussion with A. Armfield, D. Rowles and J. Commisso (KPMG) regarding updates to be made to cash tax model to include additional entities (10 additional entities).	1.4	\$350	\$ 490.00
Ashley Armfield	04/30/20	1.6 Updating cash tax model to reflect updates for addition of potential disposition of Australian entity.	1.6	\$534	\$ 854.40
Dong-Ju Shin	04/30/20	Per request from D. Rowles (KPMG US) updated the structuring deck for disposition of Mundipharma Korea on South Korea tax considerations for each step.	2.0	\$476	\$ 952.00
Becky Holtje	04/30/20	(1.3) Finalized technical research into whether certain payments are ordinary and necessary expenses to facilitate U.S. cash tax modeling; (1.0) drafting summary for M. Hoffenberg and B. Unell (both KPMG WNT) of results of research related to same for inclusion in documentation supporting cash tax modeling.	2.3	\$744	\$ 1,711.20
Ashley Armfield	04/30/20	2.3 Preparing model assumptions to be discussed during KPMG project team discussion (on same day).	2.3	\$534	\$ 1,228.20
Devon Rowles	04/30/20	Continued (from same day) updates to the cash tax model to include my designated portion of additional disposition entities.	2.4	\$350	\$ 840.00
Lukas van der Veen	04/30/20	Draft Dutch tax comments resulting from review of slide deck prepared by KPMG US on the disposal of a Dutch entity	2.5	\$565	\$ 1,412.50

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Pete DiMatteo	04/30/20	2.8 Perform international tax manager review and concurrently revised slide deck depicting various contemplated transactions relating to Luxembourg entities, including anticipated Luxembourg tax considerations regarding same	2.6	\$650	\$ 1,690.00
Ashley Armfield	04/30/20	2.6 Updating cash tax model to reflect two dispositions as prepared by KPMG staff.	2.6	\$534	\$ 1,388.40
Casey Nunez	04/30/20	2.7 Perform M&A Senior Manager review of US Trust Tax calculation in cash tax model.	2.7	\$744	\$ 2,008.80
Pete DiMatteo	04/30/20	2.7 Performed international tax manager review and concurrently revised to slide deck depicting various contemplated transactions relating to Swiss entities, including anticipated Luxembourg tax considerations regarding same.	2.7	\$650	\$ 1,755.00
Lorenzo Bellavite	04/30/20	Performed Partner level review of the structure deck ("Purdue - Italy slides"), received on Apr, 27th following the discussion with the KPMG US team, including Italian tax comments where requested.	2.8	\$476	\$ 1,332.80
Carlotta Bertu	04/30/20	Finalized updates to structure deck (received on April 27th) following discussion with the KPMG US team while concurrently drafting Italian tax comments where requested.	3.1	\$214	\$ 663.40
Isaac Hirsch	04/30/20	(2.4) Performed Managing director review of global structure deck incorporating additional sale structures in Korea, Israel, Netherlands, and Switzerland; (0.8) Perform managing director review of valuation allocation table for purposes of cash tax calculation	3.2	\$819	\$ 2,620.80
Ashley Armfield	04/30/20	3.2 Performed general cash tax model updates based on discussions with KPMG Washington National Tax practice including suggested assumptions.	3.2	\$534	\$ 1,708.80
Jess Commisso	04/30/20	3.4 Updating the glossary in the master structure deck with regards to newly added disposition entities.	3.4	\$350	\$ 1,190.00
Casey Nunez	04/30/20	2.3 Performed M&A Senior Manager review of United Kingdom Trust Tax calculation in cash tax model; 1.2 Performed M&A Senior Manager review of certain agreement tax calculations.	3.5	\$744	\$ 2,604.00
Devon Rowles	04/30/20	Updates to the cash tax model to include my designated portion of additional disposition entities	3.9	\$350	\$ 1,365.00
Jess Commisso	04/30/20	3.9 Updated the Purdue cash tax model to include asset and equity sales of two new disposition entities.	3.9	\$350	\$ 1,365.00
Massimiliano Bozzola	04/30/20	Conducted tax research (for the purpose of completing the two structure decks received on Apr, 27th) following the discussion with the KPMG US team, with specific regards to potential dispositions	3.9	\$172	\$ 670.80

19-23649-shl Doc 1233 Filed 06/05/20 Entered 06/05/20 18:54:25 Main Document Pg 68 of 76

EXHIBIT C1

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Carlotta Bertu	04/30/20	Continued (from 4/29) to update structure deck "Purdue - Italy slides" (received on April 27th) following discussion with the KPMG US team while concurrently drafting Italian tax comments where requested.	3.9	\$214	\$ 834.60
		Subtotal Tax Consulting Services			\$ 624,083.85
	Credit relat	ed to updated KPMG rates in KPMG's 1st, 2nd and 3rd monthly fee	application	s	\$ (57,147.20) (1)
		Total Bankruptcy Tax Consulting Services	1,080.3		\$ 566,936.65

⁽¹⁾ Amount includes credits related to updates to rates for the following KPMG member firms: Brazil, Germany, Italy, Singapore, Switzerland and the UK in KPMG's 1st, 2nd and 3rd monthly fee applications.

19-23649-shl Doc 1233 Filed 06/05/20 Entered 06/05/20 18:54:25 Main Document Pg 69 of 76

EXHIBIT C2

Purdue Pharma L.P. Case No. 19-23649

Non -Working Travel Time April 1, 2020 through April 30, 2020

Name	Date	Description	Hours	Rate	Amount
		no fees billed for these services in current month			
				-	Ф.
		Total Non-Working Travel Time			> -

19-23649-shl Doc 1233 Filed 06/05/20 Entered 06/05/20 18:54:25 Main Document Pg 70 of 76

EXHIBIT C3

Purdue Pharma L.P.
Case No. 19-23649
Retention Services
April 1, 2020 through April 30, 2020

Name	Date	Description	Hours	Rate	Amount
	n	o fees billed for these services in current month			
		Total Retention Services	0.0		\$ -

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	A	Amount
Wendy Shaffer	04/01/20	0.1 Review email from M. Pera (Davis Polk) regarding request to update our 2nd monthly fee statement with regards to client sensitive data; 0.6 review of data in fee statement with regards to his instructions noting items that may need to be revised - sent email to M Plangman regarding same; 0.2 email to P. Harden (KPMG) UK) to provide time/expense template and guidelines to facilitate billing in bankruptcy court; 0.2 additional communication with M. Plangman (KPMG) and S. Carlin (KPMG Office of General Counsel) regarding updates requested to Purdue 2nd monthly fee statement - via call with M Plangman and respond to email from S. Carlin; 1.5 Updated Purdue 3rd monthly fee statement to include data received from professionals as of 4/1/2020.	2.6	\$ 202	\$	525.20
Monica Plangman	04/02/20	Drafted email to S. Carlin (KPMG Office of General Counsel) and review response regarding M. Perla comments to KPMG fee statement	0.2	\$ 264	\$	52.80
Wendy Shaffer	04/02/20	0.1 Review email from M. Pera (Davis Polk) regarding suggested revisions to KPMG 2nd fee statement (prior to filing); 0.1 send copy of same to C. Nunez and H. Steinberg (KPMG); 1.3 Updated to Purdue Pharma 2nd fee app per PDF file received from Davis Polk; 0.3 Finalized (PDF) same and send to M. Plangman (KPMG) for approval; 0.6 perform additional updates to Purdue Pharma 2nd monthly fee statement per direction from M. Plangman (KPMG).	2.4	\$ 202	\$	484.80
Monica Plangman	04/03/20		0.2	\$ 264	\$	52.80
Wendy Shaffer	04/03/20	0.4 Review additional email communication from S. Carlin (KPMG Office of General counsel) related to revisions requested by Davis Polk to 2nd monthly fee statement; 0.2 communication via email with S. Carlin and M. Plangman (both KPMG) regarding next steps related to updating future fee applications with regards to same.	0.6	\$ 202	\$	121.20
Wendy Shaffer	04/07/20		1.9	\$ 202	\$	383.80
Wendy Shaffer	04/07/20	Updated exhibit C1 of Purdue March monthly fee statement to include data received from KPMG foreign professionals as of 4/7/2020.	3.9	\$ 202	\$	787.80
Wendy Shaffer	04/08/20	1.2 Updated exhibit C1 of Purdue March monthly fee statement to include data received from KPMG foreign professionals as of 4/8/2020	1.2	\$ 202	\$	242.40
Wendy Shaffer	04/09/20	2.5 Updated exhibit C1 of Purdue March monthly fee statement to include data received from KPMG US professionals of 4/9/2020; 0.3 Update exhibit C1 of Purdue March monthly fee statement to include data received from KPMG foreign professionals as of 4/9/2020	2.8	\$ 202	\$	565.60
Monica Plangman	04/10/20	Performed Associate Director review of excel files to be provided to fee examiner.	0.3	\$ 264	\$	79.20

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Wendy Shaffer	04/10/20	1.3 Created spreadsheet to provide to S. Carlin (KPMG Office of General counsel) for his review regarding requested revisions to the 2nd monthly fee statement for Purdue noting items removed and replacement language per direction from M. Plangman (KPMG)	1.3	\$ 202	\$ 262.60
Wendy Shaffer	04/10/20	0.3 Review email from E. Lisovicz (Akin Gump) regarding appointment of fee examiner and related Order; 0.1 email to KPMG Partner/ team leads to provide copy of same; (0.8) Created excel files for 1st and 2nd monthly fee statements to send to fee examiner and send to M. Plangman (KPMG) for approval prior to sending to fee examiner (as requested); 0.1 begin to draft email to D. Klauder (Purdue Fee Examiner) to provide copies of KPMG fee statements in Excel format; 1.1 updated exhibit C1 of Purdue March monthly fee statement.	2.4	\$ 202	\$ 484.80
Wendy Shaffer	04/12/20	0.1 Reviewed updated Work in Progress report to confirm billable hours for Purdue through March 31, 2020; 0.5 Updated exhibit C1 of Purdue March monthly fee statement to include data received from KPMG foreign professionals of 4/12/2020.	0.6	\$ 202	\$ 121.20
Wendy Shaffer	04/14/20	2.5 Updated exhibit C1 of Purdue March monthly fee statement to include data received from KPMG foreign professionals of 4/14/2020	2.5	\$ 202	\$ 505.00
Wendy Shaffer	04/15/20	0.1 Drafted email to M. Byun (Akin) to request instructions on procedures to participate in Purdue Pharma 1st Interim Hearing; 0.1 drafted email to H. Steinberg and C. Nunez (both KPMG) to provide instructions on procedures to participate in Purdue Pharma 1st Interim Hearing	0.2	\$ 202	\$ 40.40
Wendy Shaffer	04/16/20	0.1 Review and respond to email from C. Nunez (KPMG) regarding process to attend Purdue 1st Interim fee app Hearing	0.1	\$ 202	\$ 20.20
Wendy Shaffer	04/17/20	3.6 Updates to exhibit C1 of Purdue 3rd monthly fee statement to include data received from professionals as of 4/17/2020; 0.1 begin to prepare cover sheet to accompany Purdue Pharma 3rd monthly fee statement.	3.7	\$ 202	\$ 747.40
Wendy Shaffer	04/19/20	0.3 Updates to exhibit C1 of Purdue 3rd monthly fee statement to include data received from professionals as of 4/19/2020	0.3	\$ 202	\$ 60.60
Wendy Shaffer	04/20/20	0.3 Review email from D. Consla (Davis Polk) regarding need to re-register for Purdue 1st Interim Hearing - send email response with questions regarding same and send info to H. Steinberg and C. Nunez (both KPMG)	0.3	\$ 202	\$ 60.60
Isaac Hirsch	04/20/20	Performed International tax Managing Director review of Purdue monthly fee application and provide comments/ approval to W. Shaffer (KPMG) regarding same.	0.7	\$ 819	\$ 573.30
Wendy Shaffer	04/21/20	1.5 Updates to Purdue March monthly fee statement to include data received from professionals as of 4/21/2020.	1.5	\$ 202	\$ 303.00
Isaac Hirsch	04/22/20	(0.5) Prepare for fee application hearing by reviewing interim fee application; (1.0) Telephonic participation in fee application hearing for corporate entities within the Company's structure	1.5	\$ 819	\$ 1,228.50

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Wendy Shaffer	04/22/20	0.4 Updated exhibit C1 of Purdue March monthly fee statement to include data received from professionals as of 4/22/20; 2.0 Finalized Purdue Pharma March monthly fee statement in preparation to send to M. Plangman (KPMG) for initial review.	2.4	\$ 202	\$ 484.8
Wendy Shaffer	04/23/20	1.6 Updated exhibit C1 of Purdue 4th monthly fee statement to include data received from KPMG foreign professionals as of 4/23/2020	1.6	\$ 202	\$ 323.2
Wendy Shaffer	04/24/20	0.1 Reviewed Proposed Order provided by D. Consla (Davis Polk) for Purdue 1st Interim fee application and respond with approval of same.	0.1	\$ 202	\$ 20.2
Monica Plangman	04/26/20	Performed Associate Director review of March fee statement and concurrently provide comments.	1.7	\$ 264	\$ 448.8
Wendy Shaffer	04/27/20	0.2 Begin to draft Purdue 2nd Interim Narrative and Certification; 0.7 Updated exhibit C1 of Purdue April monthly fee statement to include data received from KPMG foreign teams as of 4/27/2020; 1.0 Updated to Purdue march monthly fee statement per M. Plangman (KPMG); 0.6 communication with C. Nunez and M. Land (both KPMG) regarding go forward to address request from Davis Polk to ensure future details mirror summary file of previous changes requested) to facilitate same.	2.5	\$ 202	\$ 505.0
Wendy Shaffer	04/28/20	1.0 Review updates to Purdue Pharma 3rd fee app made by M. Land (KPMG) per counsel request related to KPMG 2nd monthly fee statement and communication with M. Plangman (KPMG) regarding same.	1.1	\$ 202	\$ 222.2
Casey Nunez	04/28/20	Performed Lead Senior Manager review of Purdue 3rd monthly fee statement and concurrently draft review comments to provide to W. Shaffer (KPMG).	1.5	\$ 744	\$ 1,116.0
Wendy Shaffer	04/29/20	0.2 Updated exhibit C1 of March monthly fee statement to include additional time for KPMG Netherlands as of 4/29; 0.2 Communication with D. Krishnamurthy (KPMG) via email and phone regarding updates / outstanding questions related to Purdue March monthly fee statement; 0.3 Updated Purdue March monthly fee statement to include additional data from KPMG member firms and send to M. Plangman (KPMG for final approval before sending to KPMG Partner; 0.1 prepared Cover sheet for Purdue March monthly fee statement and 0.1 draft email to send copy of same with updated exhibits to MP for review/approval before sending to KPMG Partner for approval/sign-off; 0.2 drafted email to H. Steinberg (KPMG Partner) to request approval of finalized Purdue 3rd monthly fee statement documents including approval to apply electronic signature to same.	1.1	\$ 202	\$ 222.2
Teresa Williams	04/29/20	Updated designated portion of exhibit C1 of Purdue April monthly fee application per direction from W. Shaffer (KPMG)	1.5	\$ 140	\$ 210.0
Monica Plangman	04/30/20	Performed final review of March fee statement and concurrently provide comments/approval.	0.2	\$ 264	\$ 52.8

19-23649-shl Doc 1233 Filed 06/05/20 Entered 06/05/20 18:54:25 Main Document Pg 74 of 76

EXHIBIT C4

Purdue Pharma L.P. Case No. 19-23649

Name	Date	Description	Hours	Rate	Amount
Wendy Shaffer	04/30/20	2.2 Updated exhibit C1 of Purdue Pharma April monthly fee statement to include data received from professionals as of 4/30/2020; 0.4 Finalized (PDF) Purdue 3rd monthly fee statement and send to M. Plangman (KPMG for approval prior to sending to counsel for filing; 0.1 email to D. Consla (David Polk) to request filing and service of KPMG's 3rd monthly fee statement.	2.7	\$ 202	\$ 545.40
		Total Fee Application Preparation Services	47.6		\$ 11,853.80

EXHIBIT D

Purdue Pharma L.P. Case No. 19-23649

Summary of Out of Pocket Expenses April 1, 2020 through April 30, 2020

Category	Amount	
Airfare	\$	-
Lodging	\$	-
Meals	\$	-
Ground Transportation	\$	-
Miscellaneous		
Total	\$	-

19-23649-shl Doc 1233 Filed 06/05/20 Entered 06/05/20 18:54:25 Main Document Pg 76 of 76

EXHIBIT D1

Purdue Pharma L.P. Case No. 19-23649

Detail of Out of Pocket Expenses April 1, 2020 through April 30, 2020

Name	Date	Description	Amount
		Air Fare Subtotal	\$ -
		Lodging Subtotal	\$ -
		Meals Subtotal	\$ -
		Total Ground Transportation	\$ -
		Miscellaneous Subtotal	\$ -
		Total Out of Pocket Expenses	\$ -